

第1日

D A Y 1

2月17日(木)

Thursday, February 17, 2022

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)

Presidential Session

- PS1** Presidential Session 1..... 82
- PS2** Presidential Session 2..... 104

ASCO/JSMO Joint Symposium / ASCO/JSMO 合同シンポジウム

- AJS** Tumor agnostic vs tumor specific approach toward clinical developments..... 113

ESMO/JSMO Joint Symposium / ESMO/JSMO 合同シンポジウム

- EJS** Oncology Trial & Practice with/post-COVID-19 era..... 106

Joint Symposium / 合同シンポジウム

- J51** Impacts of the COVID-19 Pandemic on Cancer Management
COVID-19流行のがんマネージメントに及ぼす影響..... 123
- J52** Team-Based Medical Care for Elderly Cancer Patients Receiving Pharmacotherapy
がん薬物療法を受ける高齢者に対するチーム医療..... 124

Presidential Symposium / 会長企画シンポジウム

- PSY1** Combination Immunotherapy: Differences in other types of cancer
複合免疫療法～他がん種における相違点～..... 81
- PSY2** (Asia-Pacific Young Professionals Program) Outstanding young researchers from
Asia-Pacific countries
(アジア・パシフィック若手企画) Outstanding young researchers from Asia-Pacific
countries..... 93
- PSY3** The Future of "_____ Oncology": Deliberating the interdisciplinary development of
oncology
「〇〇オンコロジー」の未来～腫瘍学の学際的発展を考える～..... 117

Symposium / シンポジウム

- SY01** Biomarkers of Immune checkpoint inhibitors in advanced NSCLC patients
肺癌免疫療法における各種バイオマーカーの位置づけ..... 81
- SY02** The role of physical activity for cancer survivorship care
サバイバーシップケアとしての身体活動..... 87
- SY03** Multidisciplinary Approaches in the Genomic Medicine age
ゲノム医療時代の多職種連携..... 88
- SY04** Guidelines and Future Prospects for the Alleviation of Mental Distress: Toward the
Integration of Basic and Clinical Medicine
こころの苦痛の緩和のためのガイドラインと今後の展望～基礎・臨床医学の統合を目指して～
..... 89
- SY05** Challenge in tumor heterogeneity
腫瘍不均一性への挑戦..... 90

SY06	Current status and future perspectives of molecular targeted therapy for biliary tract cancer 胆道癌分子標的治療の現状と今後の展望	92
SY07	How should we face multiple challenge with novel and diverse early phase oncology drug development in Asia? Developmental Therapeutics -New Targets and New Technologies-	99
SY08	Recent advances in targeted therapy for B-cell malignancies	103
SY09	Advancement of Asian clinical trial networks with multiple stakeholders 産官学でのアジア臨床開発体制の推進	104
SY10	Recent advance of systemic therapy for unresectable hepatocellular carcinoma	110
SY11	Patient-derived models for precision cancer medicine; perspectives and challenges 個別化治療に向けた患者由来がんモデルの展望と課題	121
SY12	Challenges to Upper GI cancer 転移性上部消化管癌(食道癌、胃癌)治療の最前線	120

Educational Lecture / 教育講演

EL01	入門編 腫瘍生物学の基礎 I, II	84
EL02	入門編 腫瘍生物学の基礎 III	84
EL03	入門編 腫瘍免疫学の基礎	84
EL04	入門編 薬物療法総論I: 殺細胞性抗がん剤	84
EL05	入門編 薬物療法総論II: 分子標的薬剤	84
EL06	入門編 高齢者のがん治療	85
EL07	入門編 オンコロジー・エマージェンシー・腫瘍随伴症候群	85
EL08	入門編 副作用とその対策、支持療法	85
EL09	入門編 緩和医療	85
EL10	入門編 サイコオンコロジー・ACP(Advanced Care Planning)	85
EL11	応用編 頭頸部癌・甲状腺癌	86
EL12	応用編 食道癌・胃癌	86
EL13	応用編 大腸癌・小腸癌	86
EL14	応用編 胆道・膵臓癌	86

Meet the Experts

ME01	Frontiers in Immunotherapy	125
ME02	Microsatellite instability and Immune checkpoint inhibitors: Toward precision medicine against colorectal cancer	125
ME03	How to treat recurrent or metastatic nasopharyngeal cancer?	125
ME04	PARP inhibitors in ovarian cancer treatment	125
ME05	Precision medicine for patients with metastatic breast cancer	126

第1会場 (国立京都国際会館 1階 メインホール)

8:30-10:00 Symposium 1 / シンポジウム 1

SY01 Biomarkers of Immune checkpoint inhibitors in advanced NSCLC patients
肺癌免疫療法における各種バイオマーカーの位置づけ



Chairs : Makoto Nishio (Department of Thoracic medical Oncology, Japanese Foundation for Cancer Research)
Tatsuya Yoshida (Department of Thoracic Oncology, National Cancer Center Hospital)
司会 : 西尾 誠人 (がん研究会有明病院 呼吸器内科)
吉田 達哉 (国立がん研究センター中央病院 呼吸器内科)

SY01-1 Novel Therapies and Immunotherapy for Non-Small-Cell Lung Cancer: Finally, some progress

Roy S. Herbst (Yale Cancer Center | Yale School of Medicine)

SY01-2 Mark Awad (Dana-Farber Cancer Institute)

SY01-3 Gut microbiome as a potential biomarker of immunotherapy for advanced cancer
～ Can we just flush "it" away without examining "it" in detail? ～

Taiki Hakozaki (Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital)

がん免疫療法において腸内細菌叢解析を活用するには
～ 進行がん患者を対象とした研究の現況および課題 ～
箱崎 泰貴 (がん・感染症センター東京都立駒込病院 呼吸器内科)

SY01-4 Blood biomarker to predict response to immunotherapy

Takehito Shukuya (Department of Respiratory Medicine, Juntendo University)

血液検体を用いた免疫療法のバイオマーカー

宿谷 威仁 (順天堂大学)

SY01-5 Predictive biomarkers for cancer immunotherapy based on analysis of TILs

Shogo Kumagai (Division of Cellular Signaling National Cancer Center Research Institute)

腫瘍浸潤免疫細胞解析によるがん免疫療法の治療効果予測

熊谷 尚悟 (国立がん研究センター研究所 細胞情報学分野)

14:20-15:50 Presidential Symposium 1 / 会長企画シンポジウム 1

PSY1 Combination Immunotherapy: Differences in other types of cancer
複合免疫療法 ～他がん種における相違点～



Chairs : Yuji Miura (Department of Medical Oncology, Toranomon Hospital)
Yosuke Togashi (Department of Tumor Microenvironment, Okayama University, Graduate School of Medicine Dentistry and Pharmaceutical Sciences)
司会 : 三浦 裕司 (虎の門病院 臨床腫瘍科)
富樫 庸介 (岡山大学学術研究院医歯薬学域 腫瘍微小環境学分野)

PSY1-1 Basic insights into combined cancer immunotherapy from the perspective of the tumor immune microenvironment

Shohei Koyama (Division of Cancer Immunology, Research Institute/Exploratory Oncology Research and Clinical Trial Center (EPOC), National Cancer Center)

腫瘍免疫微小環境から考える複合免疫療法の基礎的知見

小山 正平 (国立がん研究センター 先端医療開発センター)

PSY1-2	Combined immunotherapy for non-small cell lung cancer Yoshimasa Shiraishi (Department of Respiratory Medicine, Kyushu University Hospital) 非小細胞肺癌における複合免疫療法 白石 祥理 (九州大学病院呼吸器科)
PSY1-3	Combined immunotherapy for advanced renal cell carcinoma Aiko Maejima (Department of Urology, National Cancer Center Hospital) 進行腎細胞癌における複合免疫療法 前嶋 愛子 (国立がん研究センター中央病院 泌尿器・後腹膜腫瘍科)
PSY1-4	Current status and perspectives of combined immunotherapy for hepatocellular carcinoma Satoshi Kobayashi (Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center) 肝細胞がんにおける複合免疫療法の現状と展望 小林 智 (神奈川県立がんセンター 消化器内科・肝胆膵)
PSY1-5	Combination immunotherapy for metastatic melanoma Kenjiro Namikawa (Department of Dermatologic Oncology, National Cancer Center Hospital) メラノーマに対するがん免疫療法 並川 健二郎 (国立がん研究センター中央病院 皮膚腫瘍科)
PSY1-6	Combination Immunotherapy in upper GI cancer Takashi Kojima (National Cancer Center Hospital East) 上部消化管癌における複合免疫療法 小島 隆嗣 (国立がん研究センター東病院)
16:10-18:00 Presidential Session 1	
PS1	Presidential Session 1 
Chairs :	Yuichiro Ohe (Department of Thoracic Oncology, National Cancer Center Hospital) Martin Reck (Department of Thoracic Oncology, Lungclinic)
司会 :	大江 裕一郎 (国立がん研究センター中央病院 呼吸器内科) Martin Reck (Department of Thoracic Oncology, Lungclinic)
PS1-1	Phase III of nivolumab + platinum chemotherapy + bevacizumab in untreated advanced NSQ NSCLC: Updated OS of TASUKI-52 Jin Hyoung Kang (Department of Medical Oncology, The Catholic University of Korea, Seoul St. Mary's Hospital) Discussant : Myung-Ju Ahn (Department of Medical Oncology, Samsung Medical Center)
PS1-2	CLIP1-LTK: a novel target in non-small cell lung cancer Hiroki Izumi (Department of Thoracic Oncology, National Cancer Center Hospital East) 泉 大樹 (国立がん研究センター東病院呼吸器内科) Discussant : Benjamin Solomon (Department of Medical Oncology, Peter MacCallum Cancer Centre)
PS1-3	Segmentectomy versus lobectomy in small-sized peripheral non-small cell lung cancer (JCOG0802/WJOG4607L): phase 3 trial Masahiro Tsuboi (Department of Thoracic Surgery, National Cancer Center Hospital East) 坪井 正博 (国立がん研究センター東病院 呼吸器外科) Discussant : Yi-Long Wu (Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences)

PS1-4 **A randomized phase 3 study of nintedanib with chemotherapy vs. chemotherapy alone for advanced NSCLC with IPF (J-SONIC)**

Kohei Otsubo (Department of Respiratory Medicine, Kitakyushu Municipal Medical Center / Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University)

特発性肺線維症合併進行非小細胞肺癌に対するニンテダニブ+化学療法と化学療法単独を比較するランダム化第3相試験 (J-SONIC)

大坪 孝平 (北九州市立医療センター 呼吸器内科 / 九州大学大学院医学研究院 胸部疾患研究施設)

Discussant: Martin Reck (Department of Thoracic Oncology, Lungenclinik)

PS1-5 **IMpower010: results from Asian patients in a Phase 3 study of adjuvant atezolizumab in resected stage IB-IIIa NSCLC**

Hirotsugu Kenmotsu (Division of Thoracic Oncology, Shizuoka Cancer Center)
釧持 広知 (静岡県立静岡がんセンター)

Discussant: Tetsuya Mitsudomi (Department of Thoracic Surgery, Kindai University)

ディスカサント: 光富 徹哉 (近畿大学呼吸器外科)

Day 1 (Thu)

Day 2 (Fri)

Day 3 (Sat)

Room 1

Room 2

Room 3

Room 4

Room 5

Room 6

Room 7

Room 8

Room 9

Room 10

Room 11

Room 12

Room 13

Meet the
Experts
Poster

第2+3会場 (国立京都国際会館 1階 Annex 1+2)

8:30-9:00 Educational Lecture 1 / 教育講演 1

EL01 入門編 腫瘍生物学の基礎 I, II

Biology of Cancer I, II

Rieko Ohki (National Cancer Center Research Institute)

腫瘍生物学の基礎I、II

大木 理恵子 (国立がん研究センター研究所)

9:00-9:30 Educational Lecture 2 / 教育講演 2

EL02 入門編 腫瘍生物学の基礎 III

Fundamentals of Tumor Biology III

Hiroya Taniguchi (Department of Clinical Oncology, Aichi Cancer Center Hospital)

腫瘍生物学の基礎III

谷口 浩也 (愛知県がんセンター 薬物療法部)

9:30-10:00 Educational Lecture 3 / 教育講演 3

EL03 入門編 腫瘍免疫学の基礎

Basics of Tumor Immunology

Shigehisa Kitano (The Cancer Institute Hospital of JFCR)

腫瘍免疫学の基礎

北野 滋久 (がん研究会有明病院)

10:00-10:30 Educational Lecture 4 / 教育講演 4

EL04 入門編 薬物療法総論I: 殺細胞性抗がん剤

general remarks: chemotherapy: anticancer drug

Hiroki Ueda (Oncology Center, Wakayama Medical University Hospital)

入門編: 薬物療法総論: 殺細胞抗がん剤

上田 弘樹 (和歌山県立医科大学附属病院 腫瘍センター)

10:30-11:00 Educational Lecture 5 / 教育講演 5

EL05 入門編 薬物療法総論II: 分子標的薬剤

Categories and characteristics of molecular targeting agents

Jiichiro Sasaki (Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine)

分子標的薬剤の分類と特徴

佐々木 治一郎 (北里大学医学部新世紀医療開発センター)

13:20-13:50 Educational Lecture 6 / 教育講演 6

EL06 入門編 高齢者のがん治療

Geriatric Oncology

Tetsuya Hamaguchi (Department of Medical Oncology, Saitama Medical University International Medical Center)

高齢者のがん治療

濱口 哲弥 (埼玉医科大学国際医療センター)

13:50-14:20 Educational Lecture 7 / 教育講演 7

EL07 入門編 オンコロジー・エマーゼンシー・腫瘍随伴症候群

Oncologic emergency and paraneoplastic syndrome

Takashi Tanaka (Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital)

オンコロジーエマーゼンシーと腫瘍随伴症候群

田中 喬 (国立がん研究センター中央病院)

14:20-14:50 Educational Lecture 8 / 教育講演 8

EL08 入門編 副作用とその対策、支持療法

Supportive Care in Cancer

Tateaki Naito (Division of Thoracic Oncology, Shizuoka Cancer Center)

がん支持医療と有害事象対策

内藤 立暁 (静岡県立静岡がんセンター 呼吸器内科)

14:50-15:20 Educational Lecture 9 / 教育講演 9

EL09 入門編 緩和医療

History and future of palliative care

Tomohiro Nishi (Department of Medical Oncology, Kawasaki Municipal Ida Hospital)

緩和ケアが迎ってきた歴史と未来

西 智弘 (川崎市立井田病院 腫瘍内科)

15:20-15:50 Educational Lecture 10 / 教育講演 10

EL10 入門編 サイコオンコロジー・ACP(Advanced Care Planning)

Psychosocial Care, Supported Decision Making, Advance Care Planning

Asao Ogawa (Department of Psycho-Oncology Service, National Cancer Center Hospital East)

サイコオンコロジー、Advance Care Planning

小川 朝生 (国立がん研究センター東病院 精神腫瘍科)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

15:50-16:20 Educational Lecture 11 / 教育講演 11

EL11 応用編 頭頸部癌・甲状腺癌

Future direction of the treatment of head and neck cancer and thyroid cancer

Makoto Tahara (Department of Head and Neck Medical Oncology)

頭頸部癌・甲状腺癌治療の今後の展開

田原 信 (国立がん研究センター東病院)

16:20-16:50 Educational Lecture 12 / 教育講演 12

EL12 応用編 食道癌・胃癌

Chemotherapy for advanced gastric cancer and esophageal cancer

Daisuke Sakai (Center for Cancer Genomics and Personalized Medicine, Osaka University Hospital)

進行胃がんおよび食道がんに対する化学療法

坂井 大介 (大阪大学医学部附属病院 がんゲノム医療センター)

16:50-17:20 Educational Lecture 13 / 教育講演 13

EL13 応用編 大腸癌・小腸癌

Systemic therapy for colorectal cancer and small intestine cancer

Atsuo Takashima (Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital)

大腸癌・小腸癌に対する薬物療法

高島 淳生 (国立がん研究センター中央病院)

17:20-17:50 Educational Lecture 14 / 教育講演 14

EL14 応用編 胆道・膵臓癌

Biliary tract cancer, Pancreatic cancer

Chigusa Morizane (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital)

胆道・膵臓癌

森実 千種 (国立がん研究センター中央病院)

第4会場 (国立京都国際会館 2階 Room A)

8:30-10:00 Symposium 2 / シンポジウム 2

SY02 The role of physical activity for cancer survivorship care
サブバイバーシップケアとしての身体活動



Chairs : Yutaka Matsuoka ((former department)Center for Public Health Sciences, (former affiliation) National Cancer Center, Japan)
Kiyotaka Watanabe (Department of Medicine, Teikyo University)
司会 : 松岡 豊 ((前所属)国立がん研究センター (前部署)社会と健康研究センター)
渡邊 清高 (帝京大学医学部内科学講座 腫瘍内科)

SY02-1 The role of physical activity for cancer survivorship care

Kristin L. Campbell (Department of Physical Therapy, University of British Columbia)

SY02-2 Japan's Cancer Survivorship Guidelines: Exercise edition

Katsunori Tsuji (Faculty of Bioscience and Applied Chemistry, Hosei University /
Research Fellow of Japan Society for the Promotion of Science)

がんサブバイバーシップガイドライン身体活動編

街 勝憲 (法政大学生命科学部 / 日本学術振興会特別研究員 (PD))

SY02-3 Expectations of home-based exercise research for enhancing cancer survivorship care

Yutaka Matsuoka ((former department)Center for Public Health Sciences, (former affiliation)
National Cancer Center, Japan)

がんサブバイバーシップケアを強化するための在宅運動研究への期待

松岡 豊 ((前所属)国立がん研究センター (前部署)社会と健康研究センター)

SY02-4 Prospects for cancer rehabilitation in Japan

Aiko Ishikawa (Department of Rehabilitation Medicine, Keio University School of Medicine)

がん患者リハビリテーション診療の今後

石川 愛子 (慶應義塾大学医学部リハビリテーション医学教室)

10:10-11:00 Mini-Oral Session 1

MO1 Lung Cancer / Thoracic Cancer 1 (Cytotoxic)
呼吸器1 (Cytotoxic)



Chairs : Kaoru Kubota (Department of Pulmonary Medicine and Oncology, Nippon Medical School
Hospital)
Kiyotaka Yoh (Department of Thoracic Oncology, National Cancer Center Hospital East)
司会 : 久保田 馨 (日本医科大学付属病院 呼吸器内科 / 化学療法科)
葉 清隆 (国立がん研究センター東病院 呼吸器内科)

MO1-1 A Randomized Phase III Study of Carboplatin with Nab-Paclitaxel vs Docetaxel for
elderly patients with Squamous NSCLC

Encore

Takayuki Suetsugu (Department of Respiratory Medicine, Sendai Medical Association Hospital)
末次 隆行 (川内市医師会立市民病院 呼吸器内科)

MO1-2 A phase II/III study comparing CBDCA + IRI with CBDCA + ETP for elderly patients
with ED-SCLC (JCOG1201/TORG1528)

Encore

Hiroshi Tanaka (Department of Internal Medicine, Niigata Cancer Center Hospital)

**高齢者ED-SCLCに対するカルボプラチン+エトポシドとカルボプラチン+イリノテカンの
比較第II / III相試験 (JCOG1201/TORG1528)**

田中 洋史 (新潟県立がんセンター新潟病院 内科)

MO1-3 **Prognosis and efficacy of adjuvant therapy in post-surgical NSCLC patients with WES-based genetic profiling**

Akiko Tateishi (Department of Thoracic Oncology, National Cancer Center Hospital)
立石 晶子 (国立がん研究センター中央病院 呼吸器内科)

MO1-4 **One-year incidence of venous thromboembolism in lung cancer patients in the Cancer-VTE Registry**

Tetsuya Okano (Department of Respiratory Medicine, Nippon Medical School Chiba Hokusoh Hospital)
岡野 哲也 (日本医科大学 千葉北総病院 呼吸器内科)

MO1-5 **A new risk assessment tool for venous thromboembolism complications in lung cancer considering driver gene mutation**

Yukari Tsubata (Department of Internal Medicine, Division of Medical Oncology & Respiratory Medicine, Shimane University Faculty of Medicine)
津端 由佳里 (鳥根大学医学部内科学講座 呼吸器・臨床腫瘍学)

MO1-6 **Characteristics of the tissue obtained in biopsy affecting the success rate of NGS testing in advanced NSCLC patients**

Yuki Takeyasu (Department of Thoracic Oncology, National Cancer Center Hospital)
竹安 優貴 (国立がん研究センター中央病院 呼吸腫瘍内科)

13:20-14:50 Symposium 3 / シンポジウム 3

SY03 Multidisciplinary Approaches in the Genomic Medicine age
ゲノム医療時代の多職種連携

Chairs : Masato Takahashi (Department of Breast Surgery, NHO Hokkaido Cancer Center)
Reiko Makihara (Department of Pharmacy, National Cancer Center Hospital)
司会 : 高橋 将人 (北海道がんセンター 乳腺外科)
牧原 玲子 (国立がん研究センター中央病院 薬剤部)

SY03-1 **Multidisciplinary approach for optimal care in cancer genomic medicine**

Tetsuhiro Yoshinami (Center for Cancer Genomics and Personalized Medicine, Osaka University Hospital)

がんゲノム医療における最適な選択に至るための多職種連携を考える

吉波 哲大 (大阪大学医学部附属病院 がんゲノム医療センター)

SY03-2 **Role of pharmacists for patients received Comprehensive Cancer Genome Profiling Test (CGP)**

Tsuyoshi Uemoto (Department of Pharmacy, National Cancer Center Hospital East)

包括的がんゲノムプロファイリング検査 (CGP) 後の治療における薬剤師の役割

上本 剛 (国立がん研究センター東病院 薬剤部)

SY03-3 **The role of Nurses in the Genomic Medicine from the viewpoint of CNS in genetics nursing**

Sachiko Mitarai (Department of Nursing, NTT Medical Center Tokyo)

ゲノム医療における看護職の役割について - 遺伝遺伝看護専門看護師の立場から -

御手洗 幸子 (NTT東日本関東病院 看護部 看護主任 中央診療部 遺伝相談室副室長)

SY03-4 **Multidisciplinary Approaches in the Era of Genomic Medicine: From the Perspective of a Certified Genetic Counselor**

Noriko Tanabe (Department of Genetic Medicine and Services, National Cancer Center Hospital)

ゲノム医療時代の多職種連携～認定遺伝カウンセラーの立場から～

田辺 記子 (国立がん研究センター中央病院 遺伝子診療部門)

- SY03-5 **Development of cancer genome medicine and the role of cancer consultation support centers**
 Hatoe Sakamoto (Supportive Care Center, National Cancer Center Hospital East)
がんゲノム医療の発展とがん相談支援センターの役割
 坂本 はと恵 (国立がん研究センター東病院 サポートケアセンター／がん相談支援センター)
-
- 14:50-16:20 Symposium 4／シンポジウム 4
- SY04** Guidelines and Future Prospects for the Alleviation of Mental Distress: Toward the Integration of Basic and Clinical Medicine
 こころの苦痛の緩和のためのガイドラインと今後の展望～基礎・臨床医学の統合を目指して～
- Chairs : Hiromichi Matsuoka (Department of Psycho-Oncology, National Cancer Center)
 Akihiko Shimomura (Department of Breast and Medical Oncology, National Center for Global Health and Medicine)
- 司会 : 松岡 弘道 (国立がん研究センター中央病院 精神腫瘍科/緩和ケアチーム)
 下村 昭彦 (国立国際医療研究センター病院 乳腺・腫瘍内科)
-
- SY04-1 **A preliminary presentation of the "Guidelines for Psychological Distress in Patients with Cancer" by Japan Psycho-Oncology Society**
 Daisuke Fujisawa (Division of Patient Safety / Department of Neuropsychiatry, Keio University School of Medicine)
「がん患者における気持ちのつらさガイドライン」(中間報告)
 藤澤 大介 (慶應義塾大学医学部 医療安全管理部／精神神経科)
-
- SY04-2 **Smartphone psychotherapy for reducing psychological distress among patients with cancer: a virtual randomized controlled trial**
 Tatsuo Akechi (Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences)
がん患者の精神症状に対するスマートフォン精神療法バーチャル無作為割付比較試験
 明智 龍男 (名古屋市立大学大学院医学研究科 精神・認知・行動医学分野)
-
- SY04-3 **Role of the autonomic nervous system in cancer**
 Takahiro Ochiya (Department of Molecular and Cellular Medicine, Tokyo Medical University)
がんと自律神経
 落谷 孝広 (東京医科大学 医学総合研究所 分子細胞治療研究部門)
-
- SY04-4 **Development of the Communication skill**
 Nobuya Akizuki (Department of Psycho-Oncology/Psychiatry, Tokyo Metropolitan Cancer Center and Infectious Disease Center Komagome Hospital)
コミュニケーションガイドライン開発と今後の研究課題
 秋月 伸哉 (都立駒込病院 精神腫瘍科・メンタルクリニック)
-
- SY04-5 **Efficacy of the integrated patient-centered communication support programs for oncologists and patients with rapidly progressing advanced cancer**
 Maiko Fujimori (National Cancer Center Institute for Cancer Control)
急速進行性がん患者と医師の共感的コミュニケーション促進のための統合支援プログラムの有効性
 藤森 麻衣子 (国立がん研究センターがん対策研究所)

16:20-17:50 Symposium 5 / シンポジウム 5

SY05 Challenge in tumor heterogeneity
腫瘍不均一性への挑戦



Chairs : Yosuke Togashi (Department of Tumor Microenvironment, Okayama University, Graduate School of Medicine Dentistry and Pharmaceutical Sciences)
Koichi Takahashi (Department of Leukemia, MD Anderson Cancer Center)

司会 : 富樫 庸介 (岡山大学学術研究院医歯薬学域 腫瘍微小環境学分野)
高橋 康一 (MDアンダーソンがんセンター 白血科)

SY05-1 Clonal heterogeneity and evolution and their relevance to cancer therapy

Koichi Takahashi (Department of Leukemia, MD Anderson Cancer Center)

クローン多様性と進化の臨床的意義

高橋 康一 (MDアンダーソン癌センター 白血科)

SY05-2 Genomic Evolution of Colorectal Cancer and Microenvironment

Kooshi Mimori (Kyushu University Beppu Hospital)

大腸がんゲノム進化とがん微小環境について

三森 功士 (九州大学病院別府病院)

SY05-3 Single-cell sequencing for a tumor microenvironment

Yosuke Togashi (Department of Tumor Microenvironment, Okayama University, Graduate School of Medicine Dentistry and Pharmaceutical Sciences)

腫瘍微小環境のシングルセルシーケンス

富樫 庸介 (岡山大学学術研究院医歯薬学域腫瘍微小環境学分野)

SY05-4 Spatial characterization of tumor immune-microenvironment via immunohistochemistry

Takahiro Tsujikawa (Department of Otolaryngology-Head & Neck Surgery, Kyoto Prefectural University of Medicine)

免疫組織化学を用いたがん免疫微小環境の空間的特性評価

辻川 敬裕 (京都府立医科大学 耳鼻咽喉科・頭頸部外科学教室)

第5会場 (国立京都国際会館 2階 Room B-1)

8:30-9:20 Mini-Oral Session 2

MO2 Hepatobiliary / Pancreatic Cancer 1 (Pancreatic Cancer 1)
肝胆膵1(膵がん1)

E

Chairs : Kumiko Umemoto (Department of Clinical Oncology, St. Marianna University School of Medicine)
Takeshi Terashima (Department of Gastroenterology, Kanazawa University Hospital)

司会 : 梅本 久美子 (聖マリアンナ医科大学 臨床腫瘍学講座)
寺島 健志 (金沢大学附属病院 消化器内科)

MO2-1 **Efficacy of nanoliposomal irinotecan plus 5-FU/LV in advanced pancreatic cancer: a single-center retrospective analysis**

Kenji Ikezawa (Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute)

進行膵癌におけるnanoliposomal irinotecan/5-FU/LVの有用性：単施設後ろ向き研究
池澤 賢治 (大阪国際がんセンター 肝胆膵内科)

MO2-2 **HGCSG2101: A real-world analysis of nanoliposomal irinotecan plus 5-FU/LV in pancreatic ductal adenocarcinoma**

Masayoshi Dazai (Department of Gastroenterology, Sapporo Medical Center NTT EC, Sapporo, Japan)

太宰 昌佳 (NTT東日本札幌病院 消化器内科)

MO2-3 **Nal-IRI+5-FU/LV vs 5-FU/LV in metastatic pancreatic cancer-Additional safety report of randomized Japanese phase 2 trial**

Masafumi Ikeda (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East)

池田 公史 (国立がん研究センター東病院 肝胆膵内科)

MO2-4 **Current Status of BRACAnalysis for Pancreatic Cancer - A single institution early experience**

Go Ikeda (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital)

池田 剛 (国立がん研究センター中央病院 肝胆膵内科)

MO2-5 **Homologous recombination repair-related genes in pancreatic cancer and oxaliplatin-based chemotherapy: prospective study**

Encore

Tomohiro Kondo (Department of Clinical Oncology, Kyoto University Hospital)

近藤 知大 (京都大学医学部附属病院 腫瘍内科)

MO2-6 **The current situation and issues of cancer gene panel testing in patients with unresectable pancreatic cancer**

Takuo Yamai (Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute)

山井 琢陽 (大阪国際がんセンター)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

Day 1 (Thu)	9:20-10:50	Symposium 6 / シンポジウム 6	
Day 2 (Fri)	SY06	Current status and future perspectives of molecular targeted therapy for biliary tract cancer 胆道癌分子標的治療の現状と今後の展望	E
Day 3 (Sat)	Chairs :	Takuji Okusaka (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital) Masato Ozaka (Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of JFCR)	
Room 1	司会 :	奥坂 拓志 (国立がん研究センター中央病院 肝胆膵内科) 尾坂 将人 (がん研究会 有明病院 肝胆膵内科)	
Room 2	SY06-1	Current Status and Prospects of FGFR Inhibitor Development in Japan Makoto Ueno (Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center) 本邦でのFGFR阻害薬開発の現状と展望 上野 誠 (神奈川県立がんセンター 消化器内科)	
Room 3	SY06-2	Current status and future perspectives of molecular targeted therapy for biliary tract cancer Chigusa Morizane (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital) 胆道癌分子標的治療の現状と今後の展望 森実 千種 (国立がん研究センター中央病院 肝胆膵内科)	
Room 4	SY06-3	Current Status and Prospects for the Development of Immune Checkpoint Inhibitors in Japan Masashi Kanai (Department of Therapeutic Oncology, Kyoto University) 本邦での免疫チェックポイント阻害薬開発の現状と展望 金井 雅史 (京都大学大学院医学研究科 腫瘍薬物治療学講座)	
Room 5	SY06-4	Current status and future perspectives of molecular targeted therapy for biliary tract cancer Ghassan Abou-Alfa (Memorial Sloan Kettering Cancer Center)	
Room 6	Room 7	Room 8	
Room 9	13:20-14:10	Mini-Oral Session 3	
Room 10	MO3	Gastrointestinal Cancer 1 (Upper GI Tract 1) 消化器1 (上部消化管1)	E
Room 11	Chairs :	Daisuke Takahari (Department of Gastroenterological Chemotherapy, The Cancer Institute Hospital of Japanese Foundation For Cancer Research) Shuichi Hironaka (Medical Oncology, Saitama Medical University International Medical Center)	
Room 12	司会 :	高張 大亮 (がん研有明病院 消化器化学療法科) 廣中 秀一 (埼玉医科大学国際医療センター 腫瘍内科)	
Room 13	MO3-1	Randomized phase II study of DTX versus PTX in patients with ESCC refractory to 5-FU- and platinum-based chemotherapy Takashi Ohta (Department of Clinical Oncology / Department of Gastroenterology, Kansai Rosai Hospital) フツ化ピリミジン系薬剤とプラチナ系薬剤との併用療法に不応となった進行・再発食道癌に対するドセタキセル単独療法とパクリタキセル単独療法のランダム化比較第II相試験 太田 高志 (関西労災病院 腫瘍内科/消化器内科)	
Meet the Experts	Poster		

MO3-2 **Retrospective comparison of preoperative DCF followed by surgery and dCRT for locally advanced esophageal cancer**

Mao Okada (Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital)

局所進行食道扁平上皮癌患者に対する術前DCF療法＋手術と根治的放射線療法の後方視的検討

岡田 真央 (国立がん研究センター中央病院 頭頸部・食道内科)

MO3-3 **Efficacy and safety of definitive chemoradiotherapy in patients with unresectable locally advanced esophageal SCC**

Ryosuke Kumanishi (Department of Clinical Oncology, Aichi Cancer Center Hospital)
熊西 亮介 (愛知県がんセンター薬物療法部)

MO3-4 **A Novel Clinical Prognostic Index for Advanced Gastric Cancer: Possible Contribution to the Continuum of Care**

Keitaro Shimozaki (Department of Gastroenterological chemotherapy, Cancer Institute Hospital of JFCR / Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine)
下嵯 啓太郎 (がん研究会有明病院 消化器化学療法科/慶應義塾大学医学部内科学教室 (消化器))

MO3-5 **A phase I study of FLOT as first-line treatment for advanced gastric cancer with or without severe peritoneal metastasis**

Kazuhiro Shiraishi (Department of Medical Oncology, National Hospital Organization Nagoya Medical Center)

白石 和寛 (名古屋医療センター 腫瘍内科)

MO3-6 **Safety and early efficacy of nivolumab plus trastuzumab with FU plus oxaliplatin for HER2-positive gastric cancer**

Hirokazu Shoji (Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital)

庄司 広和 (国立がん研究センター中央病院 消化管内科)

14:30-16:00 Presidential Symposium 2 / 会長企画シンポジウム 2

PSY2 (Asia-Pacific Young Professionals Program) Outstanding young researchers from Asia-Pacific countries (アジア・パシフィック若手企画) Outstanding young researchers from Asia-Pacific countries



Chairs : Solange Peters (Oncology Department, ESMO President /Centre Hospitalier Universitaire Vaudois, Lausanne University, Switzerland)

Yuichiro Ohe (Department of Thoracic Oncology, National Cancer Center Hospital)

司会 : Solange Peters (Oncology Department, ESMO President /Centre Hospitalier Universitaire Vaudois, Lausanne University, Switzerland)

大江 裕一郎 (国立がん研究センター中央病院 呼吸器内科)

PSY2-1 **From Nepal to Nippon to the North**

Bishal Gyawali (Department of Oncology, Queen's University)

Discussant : Naoki Fukuda (Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research)
ディスカッション: 福田 直樹 (がん研有明病院 総合腫瘍科)

PSY2-2 **Development of new standard therapy in biliary tract cancer: from zero to breakthrough**

Changhoon Yoo (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine)

Discussant : Akihiro Ohba (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital)
ディスカッション: 大場 彬博 (国立がん研究センター中央病院 肝胆膵内科)

PSY2-3 **My Deep Dive into the World of Sarcoma**

Tom Wei-Wu Chen (National Taiwan University Hospital)

Discussant: Kazuki Nozawa (Department of Clinical Oncology, Breast Oncology, Aichi Cancer Center Hospital)

ディスカッサント: 能澤 一樹 (愛知県がんセンター 薬物療法部、乳腺科)

Day 1 (Thu)

Day 2 (Fri)

Day 3 (Sat)

Room 1

Room 2

Room 3

Room 4

Room 5

Room 6

Room 7

Room 8

Room 9

Room 10

Room 11

Room 12

Room 13

Meet the Experts

Poster

第6会場 (国立京都国際会館 1階 Room D)

8:30-9:20 Mini-Oral Session 4

MO4 Lung Cancer / Thoracic Cancer 2 (Miscellaneous)
呼吸器2(その他)

E

Chairs : Hiroyasu Kaneda (Department of Clinical Oncology, Osaka City University)
Ikuo Sekine (Department of Medical Oncology, University of Tsukuba Faculty of Medicine)
司会 : 金田 裕靖 (大阪市立大学大学院医学研究科臨床腫瘍学)
関根 郁夫 (筑波大学 医学医療系 臨床腫瘍学)

MO4-1 Management of Infusion-related Reactions in Patients Receiving Amivantamab in the CHRYSALIS Study

Encore

Keunchil Park (Division of Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine)

MO4-2 Pharmacokinetic and dose finding study of osimertinib in patients with impaired renal function and low body weight

Encore

Takae Okuno (Division of Medical Oncology & Respiratory Medicine, Shimane University Faculty of Medicine)

奥野 峰苗 (島根大学医学部附属病院 呼吸器・化学療法内科)

MO4-3 Adverse events of sequential tyrosine kinase inhibitor following immune checkpoint inhibitor in advanced NSCLC patients

Yukiko Shimoda (Department of Thoracic Oncology, National Cancer Center Hospital)

下田 由季子 (国立がん研究センター中央病院 呼吸器内科)

MO4-4 Safety of immune checkpoint blockade in lung cancer and pre-existing autoimmune diseases: NEJ047 multi-center study

Rui Kitadai (Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan)

自己免疫疾患合併非小細胞肺癌における免疫チェックポイント阻害剤の安全性と有効性を検討する多施設後方視的研究 (NEJ047)

北台 留衣 (都立駒込病院 呼吸器内科)

MO4-5 Safety of dosage switching of Pembrolizumab from 200mg Q3W to 400 mg Q6W in advanced NSCLC patients

Ryoko Higashiyama (Department of Thoracic Oncology, National Cancer Center Hospital, Japan)

東山 量子 (国立がん研究センター中央病院)

MO4-6 Relationship between toxicities or efficacy by pemetrexed and clinical factors or single nucleotide polymorphism

Yuichiro Takeda (Department of Clinical Laboratory, National Center for Global Health and Medicine)

ペメトレキセド使用時の有害事象の発現・有効性と臨床的要因・SNPs解析の関係を探索する前向き観察研究

竹田 雄一郎 (国立国際医療研究センター病院 臨床検査科)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

9:30-11:00 Oral Session 1

01 Gastrointestinal Cancer 1 (Upper GI Tract)
消化器1(上部消化管)

E

Chairs : Taroh Satoh (Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine)
Kensho Chin (Outpatient Chemotherapy Department, Cancer Institute Hospital of JFCR)

Discussant: Izuma Nakayama (Department of Gastroenterological chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research)

司会 : 佐藤 太郎 (大阪大学大学院医学系研究科 先進癌薬物療法開発学寄附講座寄附講座)
陳 勁松 (がん研究会有明病院 外来化学療法部)

ディスカッサント: 中山 巖馬 (がん研究会有明病院 消化器化学療法科)

01-1 **Second-line tislelizumab vs chemotherapy in advanced or metastatic ESCC: RATIONALE 302 Japanese subgroup**

Hiroki Hara (Department of Gastroenterology, Saitama Cancer Center)
原 浩樹 (埼玉県立がんセンター 消化器内科)

01-2 **The effectiveness of subsequent taxanes after nivolumab therapy in patients with advanced ESCC in ATTRACTION-3**

Shun Yamamoto (Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital)
山本 駿 (国立がん研究センター中央病院 頭頸部・食道内科)

01-3 **Circulating "stem-like" PD-1₊ CD8 T cells respond to PD-1 blockade and predict clinical outcomes in esophageal cancer**

Kenro Tanoue (Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University)
田ノ上 絢郎 (九州大学大学院医学系学府病態修復内科)

01-4 **A randomized phase II trial of neoadjuvant S-1/CDDP +/- trastuzumab in HER2-positive advanced gastric cancer: JCOG1301C**

Encore

Nozomu Machida (Department of Gastroenterology, Kanagawa Cancer Center)
町田 望 (神奈川県立がんセンター)

01-5 **Bemarituzumab as a 1L Therapy for Advanced GC/GEJ - A Subgroup Analysis of East Asian Patients from the FIGHT trial**

Encore

Kensei Yamaguchi (Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research)
山口 研成 (公益財団法人がん研究会有明病院 消化器化学療法科)

01-6 **REVIVE study: An Observational Study in Chemotherapy (CTx) after Nivolumab (NIVO) for Advanced Gastric Cancer (AGC)**

Yasuhiro Sakamoto (Department of Medical Oncology, Osaki Citizen Hospital)
坂本 康寛 (大崎市民病院 腫瘍内科)

13:20-14:10 Mini-Oral Session 5

MO5 Hepatobiliary / Pancreatic Cancer 2(HCC, Pancreatic Cancer)
肝胆膵2(HCC・膵がん)



Chairs : Hiroshi Imaoka (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East)
Yasushi Kojima (Department of Gastroenterology, National Center For Global Health and Medicine)
司会 : 今岡 大 (国立がん研究センター東病院 肝胆膵内科)
小島 康志 (国立国際医療研究センター病院 消化器内科)

MO5-1 Regorafenib in advanced HCC patients who were not included in the RESORCE trial: first interim analysis

Keisuke Koroki (Department of Gastroenterology, Graduate School of Medicine, Chiba University)
興梧 慧輔 (千葉大学大学院医学研究院 消化器内科学)

MO5-2 Cabozantinib may enhance efficacy of anti-PD-1 therapy in hepatocellular carcinoma through suppression of MDSCs

Da-Liang Ou (Graduate Institute of Oncology, College of Medicine, National Taiwan University)

MO5-3 Efficacy and Patient-report outcomes of Atezolizumab/Bevacizumab for Unresectable Hepatocellular Carcinoma in Thailand

Chanchai Charonpongsuntorn (Medical Oncology Unit, Department of Internal Medicine, Srinakharinwirot University)

MO5-4 Potential Roles of Gut Microbiome in Patients with Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors

Yung-Yeh Su (National Institute of Cancer Research, National Health Research Institute, Tainan, Taiwan / Department of Oncology, National Cheng-Kung University Hospital, Tainan, Taiwan)

MO5-5 LAMC2 is a novel predictive biomarker for gemcitabine-based therapy in pancreatic ductal adenocarcinoma

Yasuyuki Okada (Department of Gastroenterology and Oncology, Tokushima University Graduate School)
岡田 泰行 (徳島大学病院 消化器内科)

MO5-6 Maintenance treatment with Gemcitabine after Gemcitabine plus Nab-Paclitaxel in advanced pancreatic cancer

Tomoko Kodama (Department of Medical Oncology, Kagoshima City Hospital)
児玉 朋子 (鹿児島市立病院 腫瘍内科)

14:10-15:00 Mini-Oral Session 6

MO6 Hepatobiliary / Pancreatic Cancer 3(Pancreatic Cancer 2)
肝胆膵3(膵がん2)



Chairs : Akiko Todaka (Division of Gastrointestinal Oncology, Shizuoka Cancer Center)
Kohei Nakachi (Department of Medical Oncology, Tochigi Cancer Center)
司会 : 戸高 明子 (静岡県立静岡がんセンター 消化器内科)
仲地 耕平 (栃木県立がんセンター 腫瘍内科)

MO6-1 Real-world treatment outcomes of metastatic pancreatic cancer in Japan: Tokushukai REAL-world Data project 03(TREAD 03)

Rai Shimoyama (Department of General Surgery, Shonankamakura General Hospital)
下山 ライ (湘南鎌倉総合病院 外科)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

MO6-2 Post-approval clinical experience with anamorelin for pancreatic cancer patients
 Mao Okada (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital)
 岡田 真央 (国立がん研究センター中央病院 肝胆膵内科)

MO6-3 Clinical and biological results of tocilizumab + rechallenge-gemcitabine/nab-paclitaxel for metastatic pancreatic cancer
 Shuichi Mitsunaga (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East / Division of Biomarker Discovery, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center)
 光永 修一 (国立がん研究センター東病院 肝胆膵内科 / 国立がん研究センター 先端医療開発センター バイオマーカー探索TR分野)

MO6-4 Evaluation of the significance of adjuvant chemotherapy in patients with stage IA pancreatic ductal adenocarcinoma
 Wataru Izumo (Surgery, Yamanashi Hospital / Department of Surgery, Institute of Gastroenterology, Tokyo Woman's Medical University)
 出雲 渉 (山梨病院 外科 / 東京女子医科大学 消化器・一般外科)

MO6-5 Clinical relevance of adjuvant chemotherapy in patients who underwent surgery following neoadjuvant modified FOLFIRINOX
 So Heun Lee (Department of Internal Medicine, Asan Medical Center)

MO6-6 Real-world Outcomes of Adjuvant Gemcitabine (GEM) vs GEM plus Capecitabine (GEMCAP) in Resected pancreatic cancer
 Sora Kang (Asan Medical Center, Ulsan University of Medicine)

15:00-15:40 Mini-Oral Session 7

MO7 Rare Cancer / Cancer of Unknown Primary 1 (Bone and soft tissue) E
 希少がん・原発不明がん1(骨軟部)

Chairs : Kohichi Takada (Department of Medical Oncology, Sapporo Medical University School of Medicine)

Kazuki Sudo (Department of Medical Oncology, National Cancer Center Hospital)

司会 : 高田 弘一 (札幌医科大学医学部腫瘍内科学講座)
 須藤 一起 (国立がん研究センター中央病院 腫瘍内科)

MO7-1 Effect of Neoadjuvant Therapies on Soft Tissue Sarcomas with Tail-like Lesions: A Multicenter Retrospective Study
 Hisaki Aiba (Department of Orthopaedic Surgery, Nagoya City University)

テールサインを有する悪性軟部腫瘍に対する術前治療の効果 :

東海骨軟部コンソーシアム多施設共同研究

相羽 久輝 (名古屋市立大学病院整形外科)

MO7-2 Assessment of pazopanib-related heart failure in patients with advanced soft tissue sarcoma

Xiaofei Wang (Department of Medical Oncology, The Cancer Institute Hospital of JFCR)

王 曉斐 (がん研究会有明病院 総合腫瘍内科)

MO7-3 A retrospective comparison of patients with sarcoma treated before and after new chemotherapeutic agent in Japan

Toshio Kubo (Center for Clinical Oncology, Okayama University Hospital)

久保 寿夫 (岡山大学病院 腫瘍センター)

M07-4 **Clinical characteristics and outcomes of primary sarcoma of breast: a single center retrospective study**
Mussadique Ali Jhatial (Department of Medical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Center Lahore)

M07-5 **Characterization of PD-1/PD-L1 immune checkpoint expression in soft tissue sarcomas**

Kazuhiko Hashimoto (Department of Orthopedics, Kindai University)

軟部肉腫におけるPD-1/PD-L1免疫チェックポイント機構発現の臨床的意義

橋本 和彦 (近畿大学 整形外科)

15:50-17:20 Symposium 7 / シンポジウム 7

SY07 How should we face multiple challenge with novel and diverse early phase oncology drug development in Asia? Developmental Therapeutics -New Targets and New Technologies-



Chairs : Toshio Shimizu (Department of Experimental Therapeutics, National Cancer Center Hospital)
Daniel SW Tan (Division of Medical Oncology, National Cancer Centre Singapore)

司会 : 清水 俊雄 (国立研究開発法人 国立がん研究センター中央病院 先端医療科)

Daniel SW Tan (Division of Medical Oncology, National Cancer Centre Singapore)

SY07-1 **New guidelines for clinical evaluation of anti-cancer drugs in Japan**

Hironobu Minami (Medical Oncology/Hematology, Kobe University Graduate School of Medicine)

抗悪性腫瘍薬の臨床評価方法に関する新しいガイドライン

南 博信 (神戸大学大学院医学研究科 腫瘍・血液内科)

SY07-2 **Where are we going to challenge to work for novel and diverse early phase oncology drug development ?**

Toshihiko Doi (Department of Experimental Therapeutics, National Cancer Center Hospital East)

早期臨床開発の向かうべき方向性

土井 俊彦 (国立がん研究センター東病院 先端医療科)

SY07-3 **Diversity and disparities in Asia: opportunities for drug development**

Daniel SW Tan (Division of Medical Oncology, National Cancer Centre Singapore)

SY07-4 **History and future of oncology early phase global clinical development in Asia**

Janna Sand Dejmek (Translational Clinical Oncology, NIBR Shanghai)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

第7会場 (国立京都国際会館 1階 Room E)

8:30-10:00 Oral Session 2

O2 Head and Neck Cancer 頭頸部

E

Chairs : Hironaga Satake (Department of Medical Oncology, Kochi Medical School)
Motoo Nomura (Department of Clinical Oncology, Kyoto University Hospital)
Discussant: Yuji Murakami (Department of Radiation Oncology, Hiroshima University Hospital)
司会 : 佐竹 悠良 (高知大学医学部腫瘍内科学講座)
野村 基雄 (京都大学医学部付属病院 腫瘍内科)
ディスカッサント: 村上 祐司 (広島大学病院 放射線治療科)

O2-1 **Trastuzumab deruxtecan in patients with HER2-expressing salivary gland carcinoma: Subgroup analysis of two Ph1 studies**

Encore

Hideaki Bando (National Cancer Center Hospital East, Chiba, Japan)
坂東 英明 (国立がん研究センター東病院)

O2-2 **The Effect of Mannitol versus Intravenous Diuretics in Preventing Cisplatin-Induced Nephrotoxicity: A Meta-Analysis**

Ramon Jr B. Larrazabal (Division of Medical Oncology, Department of Medicine, Philippine General Hospital)

O2-3 **Novel immunological classification of head and neck cancer by integrative immunogenomic analysis**

Yasuyoshi Sato (Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research / Division of Clinical Research, The Cancer Chemotherapy Center, Japanese Foundation for Cancer Research / Department of Immunotherapeutics, The University of Tokyo Hospital)

統合的免疫ゲノム解析に基づく頭頸部癌の新規免疫学的分類

佐藤 靖祥 (がん研究会有明病院 総合腫瘍科/がん研究会 がん化学療法センター臨床部/東京大学医学部附属病院 免疫細胞治療学)

O2-4 **Detection of circulating tumor DNA may be a predictor of outcome in papillary thyroid cancer with *BRAF* V600E mutation**

Encore

Ayaka Sato (Department of Breast and Endocrine Surgery, Graduate school of Medicine, The University of Tokyo / Division of Molecular Pathology, Institute of Medical Science, The University of Tokyo)

佐藤 綾花 (東京大学大学院医学系研究科 乳腺内分泌外科学/東京大学医科学研究所 人癌病因遺伝子分野)

O2-5 **Impact of proton pump inhibitors and antibiotics on efficacy of nivolumab in patients with R/M HNSCC**

Akihisa Wada (Department of Head and Neck Medical Oncology, National Cancer Center Hospital East)
和田 明久 (国立がん研究センター東病院 頭頸部内科)

O2-6 **Salvage local therapy for the progressive lesion after nivolumab in the patients with R/M SCCHN**

Masanobu Sato (Department of Head and Neck Medical Oncology, National Cancer Center Hospital East / Department of Head and Neck Surgery, National Cancer Center Hospital East)
佐藤 方宣 (国立がん研究センター東病院 頭頸部内科/国立がん研究センター東病院 頭頸部外科)

13:20-14:10 Mini-Oral Session 8

MO8 Cross-sectional Program 1 (Miscellaneous)
臓器横断プログラム1(その他)



Chairs : Toshio Kubo (Center for Clinical Oncology, Okayama University Hospital)
Seichiro Yamamoto (Department of Public Health, Shizuoka Graduate University of Public Health)
司会 : 久保 寿夫 (岡山大学病院 腫瘍センター)
山本 精一郎 (静岡社会健康医学大学院大学 社会健康医学研究科)

MO8-1 Use of Anti-cancer Drugs and Economic Burden Near the End-of-Life in Japan: Results from Claims Database

Kazunori Honda (Department of Clinical Oncology, Aichi Cancer Center Hospital)
本多 和典 (愛知県がんセンター 薬物療法部)

MO8-2 Cost analysis of treatment selection after comprehensive genomic profiling (CGP) in patients with advanced solid tumors

Takaaki Mizuno (Department of Experimental Therapeutics, National Cancer Center Hospital)
水野 孝昭 (国立がん研究センター中央病院 先端医療科)

MO8-3 Real-world outcomes of systemic therapy in Japanese cancer patients: Tokushukai REAL-world Data project (TREAD)

Rai Shimoyama (Department of General Surgery, Shonankamakura General Hospital)
下山 ライ (湘南鎌倉総合病院 外科)

MO8-4 Knowledge, Attitudes and Participants Risk of Lung Cancer in Bangladeshi Population: A Nationwide Cross-Sectional Study

Nur E Alam (Department of Biotechnology and Genetic Engineering, Mawlana Bhashani Science and Technology University, Tangail-1902, Bangladesh)

MO8-5 Evaluation of geriatric assessment for chemotherapy in older patients with gastrointestinal or biliary pancreatic cancer

Shoko Inoo (Department of Gastroenterology and Hepatology, Okayama University Hospital)
稲生 祥子 (岡山大学病院 消化器・肝臓内科)

MO8-6 A retrospective analysis of treatment for AYA cancer patients (AYAs) at our hospital

Nana Sasaki (Japanese Red Cross Kyoto Daini Hospital)
当院でのAYA世代のがん患者に対する薬物療法の治療成績と生殖医療実施に関するの後方視的検討
佐々木 奈々 (京都第二赤十字病院)

14:10-14:45 Mini-Oral Session 9

MO9 Cross-sectional Program 2 (Imaging and procedure in oncology)
臓器横断プログラム2(がん診療における画像検査・処置)



Chairs : Tatsuya Ioka (Department of Oncology Center, Yamaguchi University Hospital)
Yasushi Nagata (Department of Radiation Oncology, Hiroshima University)
司会 : 井岡 達也 (山口大学医学部附属病院 腫瘍センター)
永田 靖 (広島大学 放射線腫瘍学講座)

MO9-1 Sampling eligibility of respiratory endoscopy for comprehensive genome profile

Yuji Matsumoto (Department of Endoscopy, Respiratory Endoscopy Division/Department of Thoracic Oncology, National Cancer Center Hospital)
松元 祐司 (国立がん研究センター中央病院 内視鏡科 (呼吸器) / 呼吸器内科)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

Day 1 (Thu)	MO9-2	Usefulness of EUS-FNA for diagnosis of intraperitoneal tumors other than hepatobiliary and pancreatic cancer Toshiharu Hirose (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital) 廣瀬 俊晴 (国立がん研究センター中央病院 消化管内科)
Day 2 (Fri)	MO9-3	Usefulness of somatostatin receptor scintigraphy in urological malignancies Suguru Kadomoto (Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science) ソマトスタチン受容体シンチグラフィの泌尿器悪性腫瘍における有用性の検討 門本 卓 (金沢大学大学院医薬保健学総合研究科)
Day 3 (Sat)	Room 1	
Room 2	MO9-4	False-positive rates of urine qualitative tests during treatment with Angiogenesis inhibitors Tomomi Kashiwada (Department of Clinical Oncology, SAGA-KEN MEDICAL CENTRE KOSEIKAN) 血管新生阻害薬投与時における尿定性検査の偽陽性率 柏田 知美 (佐賀県医療センター好生館)
Room 3		
Room 4		
Room 5		14:45-15:45 Mini-Oral Session 10
Room 6	MO10	Hematologic Malignancies 1 (Myeloid) 血液1 (骨髄系腫瘍) E
Room 7		Chairs : Shigeki Ito (Department of Hematology & Oncology, Iwate Medical University) Yukio Kobayashi (Department of Hematology, IUHW Mita Hospital) 司会 : 伊藤 薫樹 (岩手医科大学医学部内科学講座血液腫瘍内科分野) 小林 幸夫 (国際医療福祉大学三田病院 医学部血液内科)
Room 8	MO10-1	Clinical significance of <i>FLT3</i> mutations in a comprehensive NGS multicenter study of AML: HM-SCREEN-Japan 01 Kentaro Fukushima (Department of Hematology and Oncology, Osaka University) 福島 健太郎 (大阪大学大学院医学系研究科 血液・腫瘍内科学)
Room 9	MO10-2	Emerging Molecular Targets in AML: IDH1/2- and Menin-related Mutations (HM-SCREEN-JAPAN01) Sunggi Chi (Department of Hematology, National Cancer Center Hospital East) 池 成基 (国立がん研究センター東病院 血液腫瘍科)
Room 10	MO10-3	Comprehensive multicenter NGS analysis of AML with BRCA mutations: HM-SCREEN-Japan 01 Hironori Arai (Div. of Hematology, Japanese Red Cross Narita Hospital) 新井 宏典 (成田赤十字病院 血液腫瘍科)
Room 11	MO10-4	Novel non-invasive biomarkers for the detection of myelofibrosis in patients with myeloproliferative neoplasms Takaaki Maekawa (Department of Clinical Oncology, National Defense Medical College Hospital / Division of Hematology, Department of Internal Medicine, National Defense Medical College) 前川 隆彰 (防衛医科大学校病院 腫瘍化学療法部 / 防衛医科大学校 内科学講座 血液内科)
Room 12	MO10-5	JAK2/miR-21/PTEN axis- an important pathway in JAK2(V617F) positive myeloproliferative neoplasias Mamta P Sumi (Department of Inflammation and immunity, Lerner Research Institute, Cleveland Clinic, Ohio, USA)
Room 13		
Meet the Experts		
Poster		

M010-6 **miR-4647 an early biomarker of outcome in Chronic Myeloid Leukaemia patients**
Sameer A Guru (Lurie Children's Hospital, Northwestern University, Chicago, USA)

15:50-17:20 Symposium 8 / シンポジウム 8

SY08 Recent advances in targeted therapy for B-cell malignancies



Chairs : Shinsuke Iida (Department of Hematology and Oncology, Nagoya City University)
Dai Maruyama (Department of Hematology Oncology, Cancer Institute Hospital of Japanese
Foundation for Cancer Research)

司会 : 飯田 真介 (名古屋市立大学大学院医学研究科 血液・腫瘍内科学分野)
丸山 大 (がん研究会有明病院 血液腫瘍科)

SY08-1 Recent advances in chimeric antigen receptor T-cell therapy

Dai Chihara (Department of Lymphoma and Myeloma, MD Anderson Cancer Center)
千原 大 (MDアンダーソンがんセンター)

SY08-2 The development of BCR signaling pathway-targeted therapy for B-cell malignancies

Wataru Munakata (Department of Hematology, National Cancer Center Hospital)

B細胞腫瘍に対するB細胞受容体シグナルを標的とした治療薬の臨床開発
棟方 理 (国立がん研究センター中央病院)

SY08-3 Recent advances in targeted therapy for B-cell malignancies

Miguel A Canales (Department of Hematology, La Paz University Hospital)

SY08-4 CD38-targeted therapy for multiple myeloma: Mechanisms of action and clinical development

Akihiro Kitadate (Department of Hematology, Nephrology, and Rheumatology, Akita University)

多発性骨髄腫における抗CD38抗体：作用機序と臨床開発
北館 明宏 (秋田大学 血液腎臓膠原病内科)

SY08-5 Action mechanisms of BCMA -targeted therapies for multiple myeloma and their promising and exciting clinical results in relapse/refractory patients

Yoichi Imai (Department of Hematology and Oncology, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo)

再発・難治多発性骨髄腫に対するBCMA標的療法の作用機序と臨床成績
今井 陽一 (東京大学医科学研究所附属病院 血液腫瘍内科)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

第8会場 (国立京都国際会館 1階 さくら)

8:30-10:00 Presidential Session 2

PS2 Presidential Session 2

E

Chairs : Hiroji Iwata (Aichi Cancer Center Hospital)
Tom Wei-Wu Chen (Department of Oncology, National Taiwan University Hospital)
司会 : 岩田 広治 (愛知県がんセンター)
Tom Wei-Wu Chen (Department of Oncology, National Taiwan University Hospital)

PS2-1 Trastuzumab Deruxtecan vs T-DM1 in HER2+ mBC in Asian Subgroup: Results of the Randomized Phase 3 Study DESTINY-Breast03

Seock-Ah Im (Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea)

Discussant : Junji Tsurutani (Advanced Cancer Translational Research Institute, Showa University)
ディスカサント: 鶴谷 純司 (昭和大学 先端がん治療研究所)

PS2-2 KEYNOTE-355 Asian Subset: Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy for Triple-Negative Breast Cancer

Toshiko Takano (The Cancer Institute Hospital of JFCR, Tokyo, Japan / Toranomon Hospital, Tokyo, Japan)

高野 利実 (がん研究会有明病院 乳腺内科)
Discussant : Tsutomu Iwasa (Department of Medical Oncology, Kindai University Faculty of Medicine)
ディスカサント: 岩朝 勤 (近畿大学医学部内科学腫瘍内科部門)

PS2-3 Neoadjuvant Pembrolizumab/Placebo + Chemo, Followed by Adjuvant Pembrolizumab/Placebo in Early TNBC: Asian Subgroup

Masato Takahashi (Department of Breast Surgery, NHO Hokkaido Cancer Center)
高橋 将人 (国立病院機構北海道がんセンター 乳腺外科)

Discussant : Naoki Niikura (Department of Breast Oncology, Tokai University)
ディスカサント: 新倉 直樹 (東海大学医学部 乳腺・腫瘍科)

PS2-4 Efficacy and safety of trastuzumab deruxtecan in HER2-expressing uterine carcinosarcoma: STATICE TRIAL (NCCH1615)

Encore
Koji Matsumoto (Hyogo Cancer Center)
松本 光史 (兵庫県立がんセンター)
Discussant : Katsutoshi Oda (Division of Integrative Genomics, The University of Tokyo)
ディスカサント: 織田 克利 (東京大学大学院 統合ゲノム学分野)

13:20-14:50 Symposium 9 / シンポジウム 9

SY09 Advancement of Asian clinical trial networks with multiple stakeholders 産官学でのアジア臨床開発体制の推進

Chairs : Yasuhiro Fujiwara (CEO, PMDA)
Tatsuo Iiyama (Department of International Trials, National Center for Global Health and Medicine (NCGM))
司会 : 藤原 康弘 (独立行政法人医薬品医療機器総合機構)
飯山 達雄 (国立国際医療センター インターナショナルトライアル部)

SY09-1 Addressing the double burden of disease in the Asian Health and Wellbeing Initiative (AHWIN) - Achieving equal access to quality healthcare services

Keizo Takemi (The House of Councillors, Japan)

アジア健康構想における二重負荷疾病構造への対応 ~質の高い医療サービスの均てん化~
武見 敬三 (参議院)

- SY09-2 **Promoting collaboration between PMDA and Regulatory agencies in Asia**
Junko Sato (Pharmaceuticals and Medical Devices Agency)
PMDAにおけるアジア規制当局との連携推進
佐藤 淳子 (医薬品医療機器総合機構)
- SY09-3 **Establishing a system for Asian development by pharmaceutical companies**
Mitsuhiro Kondo (Drug Evaluation Committee, Japan Pharmaceutical Manufacturers Association)
製薬企業によるアジア開発の体制整備
近藤 充弘 (日本製薬工業協会 医薬品評価委員会)
- SY09-4 **Imagine! the cancer research and clinical trial within Asia, by Asian for Asians**
Kan Yonemori (Department of Medical Oncology, National Cancer Center Hospital, Tokyo)
ATLASで進めよう! アジアの、アジアによる、アジアのためのがん研究・開発
米盛 勲 (国立がん研究センター中央病院 腫瘍内科)
- 15:00-15:50 Mini-Oral Session 11
- MO11** Lung Cancer / Thoracic Cancer 3 (Chemoradiotherapy)
呼吸器3 (化学放射線療法) **E**
- Chairs : Hiroaki Okamoto (Department of Respiratory Medicine and Medical Oncology, Yokohama Municipal Citizen's Hospital)
Toshiaki Takahashi (Division of Thoracic Oncology, Shizuoka Cancer Center)
- 司会 : 岡本 浩明 (横浜市立市民病院 呼吸器内科・腫瘍内科)
高橋 利明 (静岡県立静岡がんセンター 呼吸器内科)
- MO11-1 **Efficacy of durvalumab after chemoradiotherapy with daily low-dose carboplatin for unresectable locally advanced NSCLC**
Kazuki Kawajiri (Department of Thoracic Oncology, National Cancer Center Hospital)
川尻 寿季 (国立がん研究センター中央病院 呼吸器内科)
- MO11-2 **Association between soluble immune mediators and treatment outcomes for stage III NSCLC patients treated with durvalumab**
Takaaki Tokito (Division of Respiriology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine)
時任 高章 (久留米大学 内科学講座呼吸器神経膠原病内科部門)
- MO11-3 **Predictive role of HMGB1 for radiation pneumonitis in patients with NSCLC treated with definitive thoracic radiotherapy**
Shoko Isoyama (Department of Respiratory Medicine, Hiroshima University)
磯山 正子 (広島大学病院 呼吸器内科)
- MO11-4 **A retrospective analysis of locally advanced EGFR-mutated NSCLC patients with durvalumab after chemoradiotherapy**
Yoshiyasu Uchida (Department of Thoracic Oncology and Medicine, National Hospital Organization Shikoku Cancer Center)
内田 吉保 (四国がんセンター 呼吸器内科)
- MO11-5 **Dosimetry comparison between IMRT and 3DCRT/ VMAT for centrally located non-small cell lung cancer**
Eva Y W Cheung (School of Medical and Health Sciences, Tung Wah College, Hong Kong)

MO11-6 **Retrospective analysis of radiation pneumonitis in LS-SCLC patients receiving concurrent chemoradiotherapy using AHF-RT**

Kosei Doshita (Division of Thoracic Oncology, Shizuoka Cancer Center)

加速過分割照射による同時化学放射線療法を行った限局型小細胞癌における放射線肺臓炎に関する後ろ向き研究

室下 皓世 (静岡県立静岡がんセンター 呼吸器内科)

16:20-17:50 ESMO/JSMO Joint Symposium / ESMO/JSMO合同シンポジウム

EJS Oncology Trial & Practice with/post-COVID-19 era



Chairs : Solange Peters (ESMO President / Oncology Department, Centre Hospitalier Universitaire Vaudois, Lausanne University, Switzerland)
Chikashi Ishioka (Department of Clinical Oncology, Tohoku University Graduate School of Medicine)

司会 : Solange Peters (ESMO President / Oncology Department, Centre Hospitalier Universitaire Vaudois, Lausanne University, Switzerland)
石岡 千加史 (東北大学大学院医学系研究科臨床腫瘍学分野)

EJS-1 Flexibility to sustain solidity. Addressing new vulnerabilities in cancer at the time of COVID-19

Solange Peters (ESMO President / Oncology Department, Centre Hospitalier Universitaire Vaudois, Lausanne University, Switzerland)

EJS-2 COVID-19 vaccination in cancer patients

Emanuela Romano (Department of Medical Oncology, Center for Cancer Immunotherapy; INSERM U932, Department of Immunology, PSL Research University, Institut Curie, Paris, France)

EJS-3 How do we, as a society, respond to COVID-19?

Norio Ohmagari (Disease Control and Prevention Center, National Center for Global Health and Medicine)

COVID-19に社会としてどう対応するか

大曲 貴夫 (国立国際医療研究センター病院 国際感染症センター)

EJS-4 The impact of COVID-19 pandemic on the new drug development and exploration of new trial design

Noboru Yamamoto (Department of Experimental Therapeutics, National Cancer Center Hospital)

抗がん剤開発におけるCOVID-19の影響と対応および今後の戦略について

山本 昇 (国立がん研究センター中央病院 先端医療科)

第9会場 (国立京都国際会館 1階 スワン)

8:30-9:20 Mini-Oral Session 12

MO12 Hematologic Malignancies 2(Lymphoid)
血液2(リンパ系腫瘍)

E

Chairs : Kenji Ishitsuka (Department of Hematology and Rheumatology, Kagoshima University)
Yasushi Takamatsu (Division of Medical Oncology, Hematology and Infectious Diseases,
Department of Internal medicine, Fukuoka University)

司会 : 石塚 賢治 (鹿児島大学大学院医歯学総合研究科 血液・膠原病内科学)
高松 泰 (福岡大学医学部 腫瘍血液感染症内科学)

MO12-1 **Interim Results of Phase 1 study of Zandelisib(ME-401) Monotherapy in Japanese R/R Indolent B-cell non-Hodgkin Lymphoma**

Koji Izutsu (National Cancer Center Hospital)
伊豆津 宏二 (国立がん研究センター中央病院)

MO12-2 **Subcutaneous Epcoritamab+R²in Relapsed/Refractory Follicular Lymphoma: Preliminary Results From a Phase 1/2 Trial**

Encore

Kim M. Linton (The Christie NHS Foundation Trust and Manchester Cancer Research Centre, Manchester, UK)

MO12-3 **Subcutaneous Epcoritamab in Relapsed/Refractory Chronic Lymphocytic Leukemia: Preliminary Results From EPCORE CLL-1**

Encore

Anthony Mato (Memorial Sloan Kettering Cancer Center, Chronic Lymphocytic Leukemia Program, New York, NY, USA)

MO12-4 **Clinical management of other iatrogenic immunodeficiency-associated lymphoproliferative disorders**

Hidehito Fukushima (Department of Hematology and Oncology, Tokyo University Hospital)
その他の医原性免疫不全関連リンパ増殖性疾患の臨床的管理に関する後方視的解析
福島 英人 (東京大学医学部附属病院 血液・腫瘍内科)

MO12-5 **Improved survival of multiple myeloma patients treated with autologous transplantation in the modern era of new medicine**

Yutaka Shimazu (Department of Hematology, Kyoto University Hospital)
島津 裕 (京都大学医学部附属病院 血液内科)

MO12-6 **Efficacy of Lenalidomide plus Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Systematic Review**

Fenia Tandy (Faculty of Medicine, Pelita Harapan University)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

9:30-10:50 Oral Session 3

03 Hematologic Malignancies
血液



Chairs : Koji Izutsu (Department of Hematology, National Cancer Center Hospital)
Kinuko Mitani (Department of Hematology and Oncology, Dokkyo Medical University)
Discussant : Noriko Fukuhara (Tohoku University Hospital, Department of Hematology)
司会 : 伊豆津 宏二 (国立がん研究センター中央病院 血液腫瘍科)
三谷 絹子 (獨協医科大学 内科学 (血液・腫瘍))
ディスカッサント: 福原 規子 (東北大学病院血液内科)

03-1 **HM-SCREEN-Japan 01: a mutation profiling multicenter study on patients with acute myeloid leukemia**

Naoko Hosono (Department of Hematology and Oncology, University of Fukui)

初回標準治療不耐容または再発難治の急性骨髄性白血病における網羅的がん関連遺伝子異常プロファイリングの多施設共同研究

細野 奈穂子 (福井大学医学部附属病院)

03-2 **Parsaclisib in Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL): Primary Analysis From CITADEL-203**

Encore

Ryan C. Lynch (Seattle Cancer Care Alliance, University of Washington School of Medicine, Fred Hutchinson Cancer Research Center)

03-3 **Subcutaneous Epcoritamab + R-CHOP in Previously Untreated High-Risk DLBCL: Preliminary Results From a Phase 1/2 Trial**

Encore

David Belada (4th Department of Internal Medicine-Hematology, University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic)

03-4 **Outcomes from ZUMA-5 (Axicabtagene Ciloleucel) vs SCHOLAR-5 Control in Relapsed/Refractory Follicular Lymphoma (R/R FL)**

Anik R Patel (Kite, a Gilead Company, Santa Monica, CA, USA)

03-5 **Long-Term Analysis of ZUMA-5 Phase 2 Study of Axicabtagene Ciloleucel in Patients With Indolent Non-Hodgkin Lymphoma**

Sattva S. Neelapu (The University of Texas MD Anderson Cancer Center)

13:20-14:50 Oral Session 4

04 Patient Advocacy / Survivorship
患者支援・サバイバーシップ

Chairs : Keisuke Aoe (Department of Medical Oncology, National Hospital Organization Yamaguchi-Ube Medical Center)
Nagio Takigawa (Department of General Internal Medicine 4, Kawasaki Medical School)
Discussant : Akira Inoue (Department of Palliative Medicine, Tohoku University School of Medicine)
司会 : 青江 啓介 (国立病院機構山口宇部医療センター 腫瘍内科)
瀧川 奈義夫 (川崎医科大学 総合内科学4)
ディスカッサント: 井上 彰 (東北大学大学院医学系研究科 緩和医療学分野)

04-1 **Cardiovascular disease and its impact on survival in Japanese adolescent and young adult cancer survivors**

Akihiko Shimomura (Department of Breast and Medical Oncology, National Center for Global Health and Medicine)

下村 昭彦 (国立国際医療研究センター病院 乳腺・腫瘍内科)

- 04-2 **Unmet needs of adolescent and young adult patients with cancers for communication with medical staff**
 Yuko Osugi (Department of Hematology, Hyogo College of Medicine Hospital)
診療科別 adolescent and young adult (AYA) 世代のがん患者・経験者からみた医療者の態度に関するニーズ
 大杉 夕子 (兵庫医科大学病院 血液内科)
-
- 04-3 **Multi-institutional survey of thymic carcinoma patients in Hokushin region**
 Hidetaka Uramoto (Department of Thoracic Surgery, Kanazawa Medical University)
胸腺癌に対する北信4県(長野県、富山県、石川県、福井県)における多施設調査
 浦本 秀隆 (金沢医科大学 呼吸器外科)
-
- 04-4 **Linguistic validation of a Japanese version of the Chemotherapy-induced Alopecia Distress Scale**
 Yosuke Aoyama (Department of Medical Oncology, Toranomon Hospital)
日本語版 Chemotherapy-induced Alopecia Distress Scale の言語学的妥当性の検証
 青山 陽亮 (虎の門病院 臨床腫瘍科)
-
- 04-5 **Attitude and behavior of gynecologic oncologists to return to work of cancer survivors: the JGOG questionnaire survey**
 Mikiko Sato (Department of Obstetrics and Gynecology, Nihon University)
婦人科がんサバイバーの就労支援に対する婦人科医の意識調査～JGOG アンケート調査
 佐藤 美紀子 (日本大学 産婦人科)
-
- 04-6 **Gap between desired and self-determined roles of general practitioners: a multicentre questionnaire study in Japan**
 Takashi Chinen (Department of Clinical Oncology, Jichi Medical University)
がん診療における、プライマリケア医の求められる役割と自覚する役割の違い：日本での多施設アンケート
 知念 崇 (自治医科大学 臨床腫瘍科)

15:00-16:00 Mini-Oral Session 13

M013 Patient Advocacy/Survivorship 患者支援・サバイバーシップ E

- Chairs : Takeshi Isobe (Department of Internal Medicine, Division of Medical Oncology & Respiratory Medicine, Shimane University Faculty of Medicine)
 Masanobu Takahashi (Department of Medical Oncology, Tohoku University Hospital)
- 司会 : 磯部 威 (島根大学医学部 内科学講座 呼吸器・臨床腫瘍学)
 高橋 雅信 (東北大学病院 腫瘍内科)
-
- M013-1 **Geriatric-8 scores of elderly Japanese patients with cancer at the introduction of chemotherapy; A retrospective study**
 Kohji Takemura (Department of Medical Oncology, Toranomon Hospital)
日本人の高齢癌患者に対する化学療法導入時における Geriatric-8 (G8) スコアの後方視的研究
 竹村 弘司 (虎の門病院 臨床腫瘍科)
-
- M013-2 **Predicting the treatment related toxicity by Geriatric-8 geriatric assessment screening tool**
 Annop Kittiwawut (Department of Medicine, Medical Oncology unit, Chonburi hospital, Thailand)

M013-3 **Retrospective analysis of the association of geriatric assessment and outcomes in elderly gastric cancer patients**
Masahiro Ohgami (Department of Pharmacy, Ibaraki Prefectural Central Hospital, Ibaraki Cancer Center)

高齢胃癌患者における高齢者機能評価と治療成績の関連
大神 正宏 (茨城県立中央病院・茨城県地域がんセンター)

M013-4 **Geriatric assessment of esophageal cancer patients receiving drug therapy**
Junko Yamaya (Teine Keijinkai Hospital)

高齢者機能評価を用いた薬物療法を受ける食道癌患者の実態調査
山谷 淳子 (手稲溪仁会病院 看護部)

M013-5 **The Comprehensive Multidimensional Approach for Adolescents and Young Adults with Cancer Management at KHCF/C**
Encore

Salma A. Samawi (King Hussein Cancer Foundation)

M013-6 **小児がん経験者 (CCS) の移行期医療 (トランジション) に対する当院の取り組みと課題 — トランジション・モデル構築の経験から —**

Tomoko Taniyama (Dept. of Breast and Medical Oncology, National Center for Global Health and Medicine)

谷山 智子 (国立国際医療研究センター病院 乳腺・腫瘍内科)

M013-7 **Patient and Public Involvement (PPI) for clinical trials in Japan Clinical Oncology Group (JCOG)**

Aya Kimura (National Cancer Center Hospital)

JCOGにおける患者・市民参画の取り組み

木村 綾 (国立がん研究センター中央病院)

16:20-17:50 Symposium 10 / シンポジウム 10

SY10 Recent advance of systemic therapy for unresectable hepatocellular carcinoma

E

Chairs : Junji Furuse (Department of Medical Oncology, Kyorin University Faculty of Medicine)
Masafumi Ikeda (Department of Hepatobiliary & Pancreatic Oncology, National Cancer Center Hospital East)

司会 : 古瀬 純司 (杏林大学 医学部腫瘍内科学教室)
池田 公史 (国立がん研究センター東病院 肝胆膵内科)

SY10-1 **Role of lenvatinib and tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in era of immunotherapy**

Takeshi Terashima (Department of Gastroenterology, Kanazawa University Hospital)

免疫療法時代における切除不能肝細胞癌に対するレンバチニブの役割
寺島 健志 (金沢大学附属病院 消化器内科)

SY10-2 **Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice**

Kazushi Numata (Gastroenterological Center, Yokohama City University Medical Center)

切除不能な肝細胞癌患者におけるアテゾリズマブとベバシズマブ療法の安全性・有効性の実臨床での早期検討

沼田 和司 (横浜市立大学附属市民総合医療センター 消化器病センター)

SY10-3 **Systemic therapy for HCC in Asia**

Stephen Lam Chan (Department of Clinical Oncology, The Chinese University of Hong Kong)

SY10-4 **Current status of systemic therapy for uHCC in Korea**
Changhoon Yoo (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine)

SY10-5 **Future perspectives of systemic therapy for hepatocellular carcinoma**
Masafumi Ikeda (Department of Hepatobiliary & Pancreatic Oncology, National Cancer Center Hospital East)

肝細胞癌の薬物療法の今後の展望

池田 公史 (国立がん研究センター東病院 肝胆膵内科)

第10会場 (ザ・プリンス 京都宝ヶ池 1階 ロイヤルルーム)

8:30-9:20 Mini-Oral Session 14

MO14 Multidisciplinary Team Program 多職種連携プログラム

E

Chairs : Yoshiko Kitagawa (Department of Nursing, Kyushu Cancer Center)
Tomohiro Terada (Department of Pharmacy, Kyoto University Hospital)
司会 : 北川 善子 (九州がんセンター 看護部)
寺田 智祐 (京都大学医学部附属病院薬剤部)

MO14-1 Dissemination of the hazardous drugs (HDs) safe handling in the Ehime prefecture cancer cooperation council facilities.

Kenjiro Aogi (NHO Shikoku Cancer Center / Ehime Prefecture Cancer Cooperation Council)

愛媛県がん診療連携協議会施設におけるHazardous Drugs (HDs) 曝露対策の推進
青儀 健二郎 (NHO四国がんセンター／愛媛県がん診療連携協議会)

MO14-2 Hypersensitivity reactions (HSRs) at ambulatory chemotherapy center among 146,351 patients(pts) during 12 years

Mitsunori Morita (Department of Medical Oncology, Hyogo Cancer Center)

森田 充紀 (兵庫県立がんセンター 腫瘍内科)

MO14-3 遺伝子パネル検査の実施時期、及び患者への影響に関するアンケート調査

Akihiko Yarimizu (Nursing Department, College Hospital (Nishinomiya), Hyogo College of Medicine)

檜水 彰彦 (兵庫医科大学 病院 看護部)

MO14-4 Ethical issues for decision-making in genomic profiling tests from perspective of nurses

Miwa Aoki (Osaka University Graduate School of Medicine)

がん遺伝子パネル検査を受けるか否かの意思決定支援において看護師が認識している倫理的課題

青木 美和 (大阪大学大学院医学系研究科保健学専攻)

MO14-5 Development of a model for promoting palliative care education for nurses with intractable breast cancer patients

Masako Nakamura (Department of Nursing, Aichi Medical University)

難治性乳がん患者を担当する看護師への継続的な緩和ケア教育を推進するモデルの開発
中村 正子 (愛知医科大学 看護学部)

MO14-6 The impact of patient decision aids on the shared decision-making in cancer treatment

Wan-Shiuan Lin (Department of Nursing, University of Kang Ning, Taipei, Taiwan)

AJS	Tumor agnostic vs tumor specific approach toward clinical developments	E 
Chairs :	Everett Vokes (Department of Medicine, University of Chicago) Takayuki Yoshino (Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East)	
司会 :	Everett Vokes (Department of Medicine, University of Chicago) 吉野 孝之 (国立がん研究センター東病院 消化管内科)	
AJS-1	Tumor agnostic drug development: Ready for Prime Time	
	Howard Burris (Sarah Cannon)	
AJS-2	Regulatory considerations for drugs intended to treat patients agnostic of tumor type	
	Steven Lemery (Division of Oncology 3, Office of Oncologic Diseases, Center for Drug Evaluation and Research)	
AJS-3	Organ-specific and tumor-agnostic trials based on SCRUM-Japan MONSTAR-SCREEN	
	Yoshiaki Nakamura (Translational Research Support Section / Department of Gastrointestinal Oncology, National Cancer Center Hospital East)	
	SCRUM-Japan MONSTAR-SCREENを基盤とした臓器特異的・横断的治療開発	
	中村 能章 (国立がん研究センター東病院 トランスレーショナルリサーチ支援室 / 消化管内科)	
AJS-4	Current status and future perspectives of early clinical trial design for tumor agnostic/specific approach	
	Yuki Katsuya (Department of Experimental Therapeutics) 勝屋 友幾 (国立がん研究センター中央病院 先端医療科)	
13:20-14:10 Mini-Oral Session 15		
MO15	Translational Research / Clinical Pharmacology 1 (Precision Medicine)	E
	TR・臨床薬理1 (ゲノム医療)	
Chairs :	Sadakatsu Ikeda (Tokyo Medical and Dental University Hospital) Nozomu Fuse (Clinical Research Support Office, National Cancer Center Hospital East)	
司会 :	池田 貞勝 (東京医科歯科大学病院) 布施 望 (国立がん研究センター東病院 臨床研究支援部門)	
MO15-1	Assessment for the treatment lines at comprehensive genomic profiling tests in patients with advanced solid cancers	
	Kanako Hagio (Division of Clinical Cancer Genomics, Hokkaido University Hospital) 萩尾 加奈子 (北海道大学病院 がん遺伝子診断部)	
MO15-2	MicroSEC: Sequence error filtering pipeline for formalin-fixed and paraffin-embedded samples	
Encore	Masachika Ikegami (Department of Musculoskeletal Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital / Division of Cellular Signaling, National Cancer Center Research Institute / Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo)	
	池上 政周 (がん・感染症センター都立駒込病院骨軟部腫瘍科 / 国立がん研究センター研究所細胞情報学分野 / 東京大学医学部整形外科)	

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1	MO15-3 Comparison of sampling methods for next generation sequencing for patients with lung cancer through LC-SCRUM-Asia Kei Kunimasa (Department of Thoracic Oncology, Osaka International Cancer Institute) LC-SCRUM-Asiaを通じた進行期肺癌におけるNGS解析成功にむけた検体採取法の比較検討 國政 啓 (大阪国際がんセンター 呼吸器内科)
Room 2	MO15-4 Nutritional evaluation in patients with comprehensive genomic profiling Naomi Hayashi (Genomic Medicine, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research / Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research) 林 直美 (がん研究会有明病院 ゲノム診療部/総合腫瘍科)
Room 3	MO15-5 A proposal of efficient operation of expert panel for genomic medicine by pre-review meeting (pre-EP) Masahiro Yoshioka (Department of Clinical Oncology, Kyoto University Hospital, Kyoto, Japan) 吉岡 正博 (京都大学医学部附属病院 腫瘍内科)
Room 4	MO15-6 Cell-free DNA analysis of Phase I Study Evaluating Afatinib in Combination with Osimertinib Kayoko Kibata (Department of Thoracic Oncology, Kansai Medical University Hospital) 木畑 佳代子 (関西医科大学附属病院 呼吸器腫瘍内科)
Room 5	14:10-15:10 Mini-Oral Session 16
Room 6	MO16 Translational Research / Clinical Pharmacology 2 (Immunotherapy) TR・臨床薬理2(免疫療法) E
Room 7	Chairs : Kazuo Kasahara (Department of Respiratory Medicine, Kanazawa University) Shigehisa Kitano (The Cancer Institute Hospital of JFCR) 司会 : 笠原 寿郎 (金沢大学 呼吸器内科) 北野 滋久 (がん研究会有明病院)
Room 8	MO16-1 Development of adaptive immunotherapy using neoantigen (NeoAg)-specific T cell receptor (TCR)-gene transduced T cells Hidetoshi Sumimoto (Department of Medical Oncology, Shiga University of Medical Science) 住本 秀敏 (滋賀医科大学 臨床腫瘍学講座)
Room 9	MO16-2 Clinical impact of serum IgG fractions in advanced non-small cell lung cancer treated with immune checkpoint inhibitors Jun Oyanagi (Internal Medicine III, Wakayama Medical University / Center for Biomedical Sciences, CIMS, Wakayama Medical University) 免疫チェックポイント阻害剤治療を受ける進行非小細胞肺癌患者における血清免疫グロブリンFc領域の糖鎖構造の臨床的意義についての検討 小柳 潤 (和歌山県立医科大学 内科学第三講座/和歌山県立医科大学 バイオメディカルサイエンスセンター)
Room 10	MO16-3 Tumor expression of cGAS impacts on PD1/L1 inhibitors efficacy in PD-L1-high NSCLC Yuichi Ozawa (Department of Pulmonary Medicine and Medical Oncology, Wakayama Medical University) 小澤 雄一 (和歌山県立医科大学 呼吸器内科・腫瘍内科)
Room 11	MO16-4 Intestinal microbiota and gene expression reveal similarity and dissimilarity between irAE colitis and UC Kazuko Sakai (Department of Genome Biology, Kindai University Faculty of Medicine) 坂井 和子 (近畿大学医学部ゲノム生物学教室)
Room 12	
Room 13	
Meet the Experts Poster	

- MO16-5 **Gender survival disparities in the era of immune checkpoint inhibitors (ICI)**
Mohammed Hussein Safi (Department of Oncology, First Affiliated Hospital of Dalian Medical University)
- MO16-6 **S-531011, a novel anti-human CCR8 antibody: Antibody screening and evaluation of biological profiles**
Encore
Mai Yoshikawa (SHIONOGI & CO., LTD., Japan)
新規抗ヒトCCR8抗体,S-531011の創製とプロファイリング
吉川 舞 (塩野義製薬株式会社)
- MO16-7 **S-531011, a novel anti-human CCR8 antibody: antitumor effects through depleting tumor-infiltrating CCR8-positive Tregs**
Encore
Ryohei Nagai (SHIONOGI & CO., LTD.)
新規抗ヒトCCR8抗体,S-531011による腫瘍内浸潤CCR8陽性Tregs除去を介した抗腫瘍効果
永井 良平 (塩野義製薬株式会社)

15:10-16:00 Mini-Oral Session 17

- MO17** Gynecologic Cancer
婦人科 **E**
- Chairs : Shinichi Okame (Department of Gynecologic Oncology, NHO Shikoku Cancer Center)
Shin Nishio (Department of Obstetrics and Gynecology, Kurume University School of Medicine)
司会 : 大亀 真一 (国立病院機構 四国がんセンター 婦人科)
西尾 真 (久留米大学医学部産科婦人科学教室)
- MO17-1 **Clinical Practice of Comprehensive Genomic Profiling in Gynecologic Malignancies at National Cancer Center Hospital**
Yohei Chiba (Department of Medical Oncology, National Cancer Center Hospital)
千葉 洋平 (国立がん研究センター中央病院 腫瘍内科)
- MO17-2 **Immunologic changes during neoadjuvant chemotherapy in advanced-stage ovarian cancer**
Jung-Yun Lee (Yonsei University)
- MO17-3 **Diagnostic significance of HE4 as a Biomarker in Ovarian Cancer**
Harshita Dubey (Laboratory Oncology Unit, DR.B.R.A-IRCH, AIIMS, New Delhi)
- MO17-4 **Antitumor activity of niraparib for patient-derived xenografts of rare subtypes of ovarian cancer**
Hiroshi Asano (Department of Obstetrics and Gynecology, Hokkaido University)
朝野 拓史 (北海道大学 産婦人科学教室)
- MO17-5 **Clinique characteristics and result of treatment of ovarian clear cell carcinoma in Cancer National Hospital**
Yen Le (Department Medical Oncology)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

16:00-17:30 Oral Session 5

05 Breast Cancer
乳腺



Chairs : Masakazu Toi (Graduate School of Medicine, Kyoto University Hospital)
Yutaka Yamamoto (Department of Breast and Endocrine Surgery, Kumamoto University Hospital)
Discussant : Shigenori Nagai (Department of Breast Oncology, Saitama Cancer Center)
司会 : 戸井 雅和 (京都大学大学院医学研究科 外科学講座乳腺外科)
山本 豊 (熊本大学病院 乳腺・内分泌外科)
ディスカッサント: 永井 成勲 (埼玉県立がんセンター 乳腺腫瘍内科)

05-1 **Endocrine maintenance strategy with Capecitabine after BEV+PTX induction for HR+HER2- met. Breast Cancer: KBCSG-TR1214**

Tetsuhiko Yoshinami (Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University / Department of Medical Oncology, Osaka International Cancer Institute)

吉波 哲大 (大阪大学大学院医学系研究科 乳腺・内分泌外科学/大阪国際がんセンター 腫瘍内科)

05-2 **AMEERA-2: Phase 1 study of oral SERD amcenestrant (SAR439859) in Japanese women with ER+/HER2- advanced breast cancer**

Haruru Kotani (Department of Breast Oncology, Aichi Cancer Center Hospital)

小谷 はるる (愛知県がんセンター 病院 乳腺科部)

05-3 **Detection of germline BRCA1/2 variants in circulating tumor DNA from advanced breast cancer: SCRUM-Japan MONSTAR-SCREEN**

Masaya Hattori (Department of Breast Oncology, Aichi Cancer Center Hospital)

服部 正也 (愛知県がんセンター 病院 乳腺科部)

05-4 **HER2 expression and survival outcomes in HER2-low early breast cancer: retrospective multicenter cohort analysis**

Ryan Ying Cong Tan (Division of Medical Oncology, National Cancer Centre Singapore, Singapore)

05-5 **Trastuzumab Deruxtecan in Patients with HER2+ Metastatic BC: Updated Survival Results from a Ph2 Study, DESTINY-Breast01**

Encore

Toshinari Yamashita (Kanagawa Cancer Center)

山下 年成 (神奈川県立がんセンター)

05-6 **Economic burden of breast cancer in Japan: Evidence-based systematic literature review**

Md Azharuddin (School of Pharmaceutical Education and Research, Jamia Hamdard)

第11+12会場 (ザ・プリンス 京都宝ヶ池 B2階 プリンスホール1+2)

9:30-11:00 Presidential Symposium 3 / 会長企画シンポジウム 3

PSY3 The Future of "_____ Oncology": Deliberating the interdisciplinary development of oncology
「〇〇オンコロジー」の未来 ~腫瘍学の学際的發展を考える~

Chairs : Hironobu Minami (Medical Oncology/Hematology, Kobe University Graduate School of Medicine)
Manabu Muto (Department of Therapeutic Oncology, Kyoto University)

司会 : 南 博信 (神戸大学大学院医学研究科 腫瘍・血液内科)
武藤 学 (京都大学 医学研究科腫瘍薬物治療学講座)

PSY3-1 Cardiac Energy Metabolism as a Therapeutic Target against Chemotherapy-related Cardiac Dysfunction (CTRCD)

Satoaki Matoba (Department of Cardiovascular Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine)

がん治療関連心機能障害 (CTRCD) に対する心臓エネルギー代謝制御からのアプローチ
の場 聖明 (京都府立医科大学 大学院医学研究科 循環器内科)

PSY3-2 Future prospects of Stroke Oncology

Teruyuki Hirano (Department of Stroke and Cerebrovascular Medicine, Kyorin University)

Stroke Oncologyの展望

平野 照之 (杏林大学医学部 脳卒中医学)

PSY3-3 Diabeto-oncology with reference to type 1 diabetes related to anti-PD-1 therapy

Akihisa Imagawa (Department of Internal Medicine (I), Osaka Medical and Pharmaceutical University)

腫瘍糖尿病学の展望 一免疫チェックポイント阻害薬と1型糖尿病を中心に

今川 彰久 (大阪医科大学 内科学I)

PSY3-4 Onconephrology: its current status and challenges

Motoko Yanagita (Department of Nephrology, Kyoto University Graduate School of Medicine)

Onconephrology : その現状と課題

柳田 素子 (京都大学医学研究科腎臓内科学)

PSY3-5 The future of "Onco-〇〇"

Hironobu Minami (Medical Oncology/Hematology, Kobe University Graduate School of Medicine)

「Onco-〇〇」の未来

南 博信 (神戸大学大学院医学研究科 腫瘍・血液内科)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

13:10-14:40 Oral Session 6

06

Lung Cancer / Thoracic Cancer 1 (Molecularly-targeted therapy EGFR,ALK)
呼吸器1(分子標的 EGFR, ALK)



Chairs : Koichi Goto (Department of Thoracic Oncology, National Cancer Center Hospital East)
Takashi Seto (Department Thoracic Oncology, NHO Kyushu Cancer Centre)

Discussant: Hidetoshi Hayashi (Department of Medical Oncology, Kindai University)

司会 : 後藤 功一 (国立がん研究センター東病院 呼吸器内科)

瀬戸 貴司 (国立病院機構 九州がんセンター 呼吸器腫瘍科)

ディスカッサント: 林 秀敏 (近畿大学医学部内科学腫瘍内科)

06-1 **Randomized phase II study of osimertinib+bevacizumab vs. osimertinib for untreated patients with EGFR+non-squamous NSCLC**

Encore

Terufumi Kato (Department of Thoracic Oncology, Kanagawa Cancer Center)

EGFR遺伝子変異陽性非扁平上皮非小細胞肺癌に対するオシメルチニブ+ベバシズマブ併用とオシメルチニブ単剤を比較するランダム化第2相試験; WJOG9717L

加藤 晃史 (神奈川県立がんセンター 呼吸器内科)

06-2 **ORCHARD osimertinib + savolitinib interim analysis: PhII platform study in EGFRm NSCLC after progression on osimertinib**

Encore

Isamu Okamoto (Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University)

岡本 勇 (九州大学 呼吸器科)

06-3 **The significance of ultra-low EGFR T790M mutations on EGFR-TKI efficacy in patients with NSCLC -the WJOG13119L study-**

Takeshi Masuda (Department of Respiratory Medicine, Hiroshima University Hospital)

益田 武 (広島大学病院呼吸器内科)

06-4 **A rP2 study comparing Nivo with CBDCA-PEM for EGFRm NSCLC acquired TKI-resistance not due to T790M (WJOG8515L)**

Encore

Atsushi Nakamura (Department of Pulmonary Medicine, Sendai Kousei Hospital)

中村 敦 (仙台厚生病院 呼吸器内科)

06-5 **Brigatinib (BRG) Versus Crizotinib (CRZ) in Patients With ALK TKI-Naive ALK-Positive NSCLC: Final Results From ALTA-1L**

Encore

Hye Ryun Kim (Yonsei Cancer Center, Yonsei University College of Medicine)

06-6 **Resistance mechanisms to alectinib in pts with ALK+ NSCLC: interim data of the multicenter observational study (ALCURE)**

Naoki Haratake (Department of Surgery and Science, Kyushu University Hospital)

原武 直紀 (九州大学病院 呼吸器外科)

07 Gastrointestinal Cancer 2 (Lower GI Tract-Colorectal Cancer 1)
消化器2(下部消化管-大腸癌1)

Chairs : Atsuo Takashima (Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital)
Tetsuya Hamaguchi (Department of Medical Oncology, Saitama Medical University International Medical Center)

Discussant : Hideaki Bando (Department of Gastrointestinal Oncology, National Cancer Center Hospital East)

司会 : 高島 淳生 (国立がん研究センター中央病院 消化管内科)
濱口 哲弥 (埼玉医科大学国際医療センター 腫瘍内科)

ディスカッサント: 坂東 英明 (国立がん研究センター東病院 消化管内科)

07-1 A Phase III trial of sequential versus combination in metastatic colorectal cancer: C-Cubed study

Yasuhiro Shimada (Clinical Oncology Division, Kochi Health Sciences Center)
島田 安博 (高知医療センター 腫瘍内科)

07-2 FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type mCRC: the subgroup-analysis of DEEPER trial (JACCRO CC-13)

Taichi Yabuno (Department of Gastrointestinal Surgery, Yokohama Municipal Citizen's Hospital)
薮野 太一 (横浜市立市民病院 消化器外科)

07-3 Pembrolizumab vs chemotherapy in MSI-H / dMMR metastatic colorectal cancer: KEYNOTE-177 final analysis Asia subgroup

Takayuki Yoshino (National Cancer Center Hospital East)
吉野 孝之 (国立がん研究センター東病院)

07-4 Ramucirumab plus FOLFIRI for RAS wild-type mCRC refractory to 1st-line treatment with anti-EGFR antibody: JACCRO CC-16

Tamotsu Sagawa (Division of Gastroenterology, National Hospital Organization Hokkaido Cancer Center)

抗EGFR抗体薬併用化学療法に不応/不耐となった進行再発大腸癌患者に対する2次治療:
FOLFIRI/ラムシルマブ併用療法の第II相試験: JACCRO CC-16

佐川 保 (独立行政法人国立病院機構北海道がんセンター 消化器内科)

07-5 Exploratory analysis of baseline tumor burden in the TRUSTY study: Phase 2/3 study of 2nd-line FTD/TPI + BEV for mCRC

Masato Nakamura (Aizawa Comprehensive Cancer Center, Aizawa Hospital)
中村 将人 (相澤病院 がん集学治療センター化学療法科)

16:00-17:55 Symposium 12 / シンポジウム 12

SY12 Challenges to Upper GI cancer
転移性上部消化管癌(食道癌、胃癌)治療の最前線



Chairs : Markus Moehler (Department of Medicine, Johannes-Gutenberg University Clinic, Mainz, Germany)
Takako Nakajima (Department of Early Clinical Development, Kyoto University Graduate School of Medicine)

司会 : Markus Moehler (Department of Medicine, Johannes-Gutenberg University Clinic, Mainz, Germany)
中島 貴子 (京都大学大学院医学研究科 早期医療開発学)

SY12-1 Immunotherapy in advanced esophagogastric cancer

Markus Moehler (Department of Medicine, Johannes-Gutenberg University Clinic, Mainz, Germany)

SY12-2 Precision medicine in gastric cancer: current status and how to improve treatment outcomes

Min-Hee Ryu (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine)

SY12-3 Precision medicine for esophageal cancer

Hiroki Hara (Department of Gastroenterology, Saitama Cancer Center)

食道癌におけるprecision medicine

原 浩樹 (埼玉県立がんセンター 消化器内科)

SY12-4 Current status and future perspective of perioperative chemotherapy for locally advanced gastric cancer

Daisuke Takahari (Department of Gastrointestinal Chemotherapy, The Cancer Institute Hospital of JFCR)

切除可能進行胃がんにおける周術期化学療法の現状と展望

高張 大亮 (がん研究会有明病院)

SY12-5 Challenges to Upper GI cancer

Akihito Kawazoe (Department of Gastrointestinal Medical oncology, National Cancer Center Hospital East, Chiba, Japan)

転移性上部消化管癌(食道癌、胃癌)治療の最前線

川添 彬人 (国立がん研究センター東病院)

SY12-6 CAR T-cells for the treatment of upper GI cancers: lessons learned from hematology

Michael von Bergwelt-Baildon (Department of Hematology and Medical Oncology, Ludwig-Maximilians-University Muenchen)

第13会場 (ザ・プリンス 京都宝ヶ池 B2階 ゴールドルーム)

8:30-10:00 Symposium 11 / シンポジウム 11

SY11 Patient-derived models for precision cancer medicine: perspectives and challenges
個別化治療に向けた患者由来がんモデルの展望と課題

E

Chairs : Eiji Shinozaki (Department of gastroenterological chemotherapy, Cancer Institute Hospital of JFCR)
Senthil K. Muthuswamy (Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School)
司会 : 篠崎 英司 (がん研究会有明病院 消化器化学療法科)
Senthil K. Muthuswamy (Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School)

SY11-1 Precision medicine in the clinic: the human avatar

Razelle Kurzrock (Professor of Medicine, Associate Director, Clinical Research MCW Cancer Center and Genomic Sciences and Precision Medicine Center / Chief Medical Officer, Executive Committee, Worldwide Innovative Network (WIN) for Personalized Cancer Therapy (non-profit) / Adjunct Professor, University of Nebraska)

SY11-2 Tumor Organoid Models for Translational Research and Co-Clinical Applications

Senthil K. Muthuswamy (Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School)

SY11-3 Cancer tissue-originated spheroids and precision medicine

Masahiro Inoue (Department of Clinical Bio-resource Research and Development, Graduate School of Medicine Kyoto University)

Cancer tissue-originated spheroids法の精密化医療への応用

井上 正宏 (京都大学大学院医学研究科 クリニカルバイオリソース研究開発講座)

SY11-4 Non-clinical patient-derived models for co-clinical trial

Yoshikatsu Koga (Department of Strategic Programs, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center)

並走臨床試験における非臨床患者由来モデル

古賀 宣勝 (国立がん研究センター 先端医療開発センター 研究企画推進部門)

13:10-14:00 Mini-Oral Session 18

MO18 Breast Cancer 1 (Systemic treatment, Survivors)
乳腺1 (薬物療法・サバイバーシップ)

E

Chairs : Kazuhiro Araki (Department of Medical Oncology, Gunma Prefrectal Cancer Center)
Yasuhiro Yanagita (Department of Breast Oncology, Gunma Prefrectal Cancer Center)
司会 : 荒木 和浩 (群馬県立がんセンター 腫瘍内科・通院治療センター)
柳田 康弘 (群馬県立がんセンター 乳腺科)

MO18-1 Impact of Cachexia on Survival Before First-line Chemotherapy for Metastatic Breast Cancer

Kazuki Nozawa (Department of Breast Oncology, Aichi Cancer Center Hospital)

転移再発乳癌におけるがん悪液質の生存に与える影響

能澤 一樹 (愛知県がんセンター乳腺科)

MO18-2 A phase II trial of neoadjuvant apatinib combined with nab-paclitaxel and carboplatin in triple-negative breast cancer

Tianyu Zeng (Department of Oncology, the First Affiliated Hospital of Nanjing Medical University)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

MO18-3 A novel information sharing system via YouTube to provide breast cancer information and to raise public breast awareness
 Asumi Iesato (Department of Pathology, Beth Israel Deaconess Medical Center / BC Tube Association)
 家里 明日美 (バス・イスラエル・ディーコネス・メディカルセンター 病理学講座／一般社団法人 BC Tube)

MO18-4 The efficacy of palbociclib and subsequent therapy
 Naoko Iwamoto (Department of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital)
パルボシクリブの有効性と次治療について
 岩本 奈織子 (都立駒込病院 がん・感染症センター)

MO18-5 Survival 11: The nomogram and android application to estimate the survival rate of breast cancer subjects in Indonesia
 Citra Aryanti (Division of Surgical Oncology, Department of Surgery, Udayana University, Denpasar, Bali, Indonesia)

MO18-6 Dynamic change in absolute lymphocyte counts during eribulin therapy predicts overall survival in advanced breast cancer
 Shogo Nakamoto (Department of Breast and Thyroid Gland Surgery, Fukuyama City Hospital)
 中本 翔伍 (福山市民病院 乳腺甲状腺外科)

14:00-14:50 Mini-Oral Session 19

MO19 Breast Cancer 2 (Basic science, Biomarker)
 乳腺2 (基礎研究・バイオマーカー)



Chairs : Makiko Ono (Cancer Institute Hospital of the JFCR, Department of Medical Oncology)
 Nahomi Tokudome (Department of Pulmonary Medicine and Medical Oncology, Wakayama Medical University)

司会 : 小野 麻紀子 (公益財団法人 がん研有明病院 総合腫瘍科)
 徳留 なほみ (和歌山県立医科大学 内科学第三講座)

MO19-1 Ubiquitin ligase NEDD4 promotes degradation of estrogen receptor in breast cancer and affects prognosis
 Yutaka Natori (Department of Medical Oncology, Fukushima Medical University)
 名取 穰 (福島県立医科大学 腫瘍内科)

MO19-2 Impact of adjuvant chemotherapy and radiotherapy on tumor microenvironment in recurrent breast cancer
 Shu Yazaki (Department of Medical Oncology, National Cancer Center Hospital)
 矢崎 秀 (国立がん研究センター中央病院 腫瘍内科)

MO19-3 PD-L1 expression in patients with HER2-negative advanced breast cancer: A multicenter retrospective study
 Junichiro Watanabe (Department of Breast Oncology, Juntendo University Graduate School of Medicine / Division of Breast Oncology, Shizuoka Cancer Center)
 渡邊 純一郎 (順天堂大学大学院医学研究科 乳腺腫瘍学／静岡県立静岡がんセンター 女性内科)

MO19-4 lncRNA ANRIL, TUG1, UCA1, and HIT expression in breast cancer patients Serum sample
 Masroor Ali Beg Mirza (Faculty of Medicine, Department of Biochemistry, Alatoo International University, Bishkek, Kyrgyzstan / Centre for Promotion of Medical Research, Alatoo International University, Kyrgyzstan)

MO19-5	To establish a simulated hormonal microenvironment culture model for advancement of PDT modality in gynecological cancer Ellie S.M. Chu (School of Medical and Health Sciences, Tung Wah College, Hong Kong)
MO19-6	Metabolic syndrome increase breast cancer risk among postmenopausal women Elrich M. Haryanto (Faculty of medicine, Pelita Harapan University)
14:50-16:20	Joint Symposium 1 (JCA/JSCO/JSMO) / 合同シンポジウム 1 (日本癌学会/日本癌治療学会/日本臨床腫瘍学会)
JS1	Impacts of the COVID-19 Pandemic on Cancer Management COVID-19流行のがんマネージメントに及ぼす影響
Chair	: Takeshi Terashima (Department of Gastroenterology, Tokyo Dental College Ichikawa General Hospital)
司会	: 寺嶋 毅 (東京歯科大学市川総合病院 呼吸器内科)
JS1-1	Impact of COVID-19 for cancer screening and cancer treatment in Japan Hirokazu Takahashi (National Cancer Center Institute for Cancer Control) 新型コロナウイルス感染症によるがん検診およびがん診療への影響 高橋 宏和 (国立がん研究センターがん対策研究所)
JS1-2	Study of the importance of screening for safe cancer treatment and surgery in COVID-19 pandemic Yutaka Takigawa (Department of Surgery, Tokyo Dental College Ichikawa General Hospital / COVID-19 Task Force, Tokyo Dental College Ichikawa General Hospital) COVID-19禍における安全ながん治療・手術を行うためのスクリーニングの重要性についての検討—当院における院内クラスター発生予防への取り組み— 瀧川 穰 (東京歯科大学市川総合病院 外科 / 東京歯科大学市川総合病院 コロナ対策本部)
JS1-3	Impact of COVID-19 on lung cancer treatment Kenji Sugio (Department of Thoracic and Breast Surgery, Oita University) COVID-19が肺がん診療に及ぼした影響 杉尾 賢二 (大分大学 呼吸器・乳腺外科)
JS1-4	SARS-CoV-2 Antibody Status in patients with cancer during the COVID-19 Pandemic Tatsuya Yoshida (Department of Thoracic Oncology, National Cancer Center Hospital) がん患者におけるSARS-CoV-2抗体価の変化 吉田 達哉 (国立がん研究センター中央病院 呼吸器内科)
JS1-5	Management of hematological disorders in COVID-19 pandemic Masao Hagihara (Department of Hematology, Eiju General Hospital) COVID-19パンデミックにおける血液疾患のマネジメント 萩原 政夫 (永寿総合病院 血液内科)
JS1-6	Host genetics in COVID-19 infection Yukinori Okada (Department of Statistical Genetics, Osaka University Graduate School of Medicine) 新型コロナウイルス感染症に対するホストゲノムの関わり 岡田 随象 (大阪大学大学院医学系研究科 遺伝統計学)

16:20-17:50 Joint Symposium 2 (JSCN/JSMO) / 合同シンポジウム 2 (日本がん看護学会/日本臨床腫瘍学会)

JS2 Team-Based Medical Care for Elderly Cancer Patients Receiving Pharmacotherapy
がん薬物療法を受ける高齢者に対するチーム医療

Chairs : Kaori Yagasaki (Faculty of Nursing and Medical Care, Keio University)
Masato Takahashi (Department of Breast Surgery, NHO Hokkaido Cancer Center)
司会 : 矢ヶ崎 香 (慶應義塾大学 看護医療学部)
高橋 将人 (北海道がんセンター 乳腺外科)

JS2-1 Multidisciplinary cooperation for elderly cancer patients receiving chemotherapy in Japan

Fumio Nagashima (Department of Medical Oncology, Kyorin University)
がん薬物療法を受ける高齢者に対するチーム医療
長島 文夫 (杏林大学 腫瘍内科)

JS2-2 The Role of Family doctors in Home Medical Care

Tesshu Kusaba (Hokkaido Centre for Family Medicine)
総合診療医が在宅医療で果たす役割
草場 鉄周 (北海道家庭医療学センター)

JS2-3 Issues surrounding the care of elderly cancer patients

Hikaru Haruki (Department of Nursing, The University of Tokyo Hospital)
高齢がん患者への支援の実際と課題 病院看護師の立場から
春木 ひかる (東京大学医学部附属病院 看護部)

JS2-4 Leverage visiting nurse strengths seeing elderly cancer patients as person

Satsuki Uno (Family Hospice Kobe Tarumi House)
高齢がん患者を「生活者」として捉えている強みをチームに活かす～在宅の看護師の立場から～
宇野 さつき (ファミリー・ホスピス神戸垂水ハウス)

JS2-5 Social support for elderly cancer patients in collaboration with the community

Hatoe Sakamoto (Supportive Care Center, National Cancer Center Hospital East)
地域と協働して展開する高齢がん患者への社会的支援
坂本 はと恵 (国立がん研究センター東病院 サポートケアセンター/がん相談支援センター)

Meet the Experts会場① (国立京都国際会館 2階 Room I)

8:30-9:30 Meet the Experts 1

ME01 Frontiers in Immunotherapy

E

Chairs : Emi Noguchi (Department of Medical Oncology, National Cancer Center Hospital)
Yuko Tanabe (Department of Medical Oncology, Toranomon Hospital)
司会 : 野口 瑛美 (国立がん研究センター中央病院 腫瘍内科)
田辺 裕子 (虎の門病院 臨床腫瘍科)

ME01 Frontiers in Immunotherapy

Hope S. Rugo (UCSF Helen Diller Family Comprehensive Cancer Center)

9:55-10:55 Meet the Experts 2

ME02 Microsatellite instability and Immune checkpoint inhibitors: Toward precision medicine against colorectal cancer

E

Chair : Toshihiko Matsumoto (Department of Medical Oncology, Kobe City Medical Center General Hospital)
司会 : 松本 俊彦 (神戸市立医療センター中央市民病院 腫瘍内科)

ME02 Microsatellite instability and Immune checkpoint inhibitors: Toward precision medicine against colorectal cancer

Tae Won Kim (Department of Oncology, Asan Medical Center)

13:20-14:20 Meet the Experts 3

ME03 How to treat recurrent or metastatic nasopharyngeal cancer?

E

Chair : Naomi Kiyota (Cancer Center, Kobe University Hospital)
司会 : 清田 尚臣 (神戸大学医学部附属病院 腫瘍センター)

ME03 How to treat recurrent or metastatic nasopharyngeal cancer?

Anthony T.C. Chan (Department of Clinical Oncology, The Chinese University of Hong Kong / Sir Y K Pao Centre for Cancer, The Chinese University of Hong Kong / Hong Kong Cancer Institute, The Chinese University of Hong Kong)

14:55-15:55 Meet the Experts 4

ME04 PARP inhibitors in ovarian cancer treatment

E

Chair : Tadaaki Nishikawa (Department of Medical Oncology, National Cancer Center Hospital)
司会 : 西川 忠暁 (国立がん研究センター中央病院 腫瘍内科)

ME04 PARP inhibitors in ovarian cancer treatment

Mansoor Raza Mirza (The Nordic Society of Gynecological Oncology and Rigshospitalet-Copenhagen University Hospital)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Meet the Experts
Poster

16:20-17:20 Meet the Experts 5

ME05 Precision medicine for patients with metastatic breast cancer



Chair : Yoshinori Imamura (Medical Oncology / Hematology, Kobe University Hospital)
司会 : 今村 善宣 (神戸大学医学部附属病院 腫瘍・血液内科)

ME05 Precision medicine for patients with metastatic breast cancer

Fabrice Andre (Gustave Rouss, Université Paris Saclay)

P1	Hematologic Malignancies 1
	血液 1
P1-1	<p>Outcomes of DLBCL with primary or secondary involvement of breast: a case series Mussadique Ali Jhatial (Department of Medical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Center Lahore)</p>
P1-2	<p>Decitabine efficacy and safety in the management of acute myeloid leukemia: A meta-analysis of real-world evidence Md Sarfaraj Hussain (Lord Budha Koshi Pharmacy College)</p>
P1-3	<p>The Efficacy of Lenalidomide plus Rituximab in Lymphoma Patients with ECOG Performance Status ≤ 2: A Systematic Review Marilyn Suciningtias (Faculty of Medicine, Pelita Harapan University)</p>
P1-4	<p>Lenalidomide-Bortezomib-Dexamethasone Efficacy in Multiple Myeloma with ECOG Performance Status: A Systematic Review Celine Chrystelle (Faculty of Medicine, Pelita Harapan University)</p>
P1-5	<p>Study of Clinical behavior and treatment outcome in patients of Extra Nodal Non Hodgkin Lymphoma Chaturbhuj Agrawal (Consultant Medical Oncology, RGCI, New Delhi)</p>
P1-6	<p>The association of spleen to liver ratio (SLR) on PET scan with relapse of Hodgkin lymphoma Suyeon Bang (Oncology and Hematology Clinic, Department of Internal Medicine, Pusan National University Yangsan Hospital)</p>
P1-7	<p>Clinical Outcomes in Relapsed/Refractory Follicular Lymphoma: A Systematic Literature Review and Meta-Analysis Anik R. Patel (Kite, a Gilead Company, Santa Monica, CA, USA)</p>
P1-8	<p>Neutrophil-Lymphocyte Ratio Predicts Outcome of Diffuse Large B Cell Lymphoma: A Systematic Review and Meta Analysis Yang Yang E. Arjuna (Faculty of Medicine, Pelita Harapan University)</p>
P1-9	<p>C-terminal domain of Versican promotes myeloma cell proliferation, migration & invasion by altering FAK/STAT signaling Nidhi Gupta (Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India)</p>
P1-10	<p>Mutation of CREB Binding Protein with relapse of Acute Lymphoid Leukemia: A Systematic Review Yewan Lim (Faculty of Medicine, Pelita Harapan University)</p>
P1-11	<p>Real-World Treatment Patterns in Multiple Myeloma: Japan MDV Claims Database Analysis (2016-2020) Kenshi Suzuki (Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan) 鈴木 憲史 (日本赤十字社医療センター 血液内科)</p>
P1-12	<p>Serum Vitamin D Level Associated to Prognosis of Non-Hodgkin Lymphoma Patients: A Systematic Review and Meta-Analysis Alexander E. Purnomo (Faculty of Medicine, Pelita Harapan University)</p>

11:10-11:55 Poster Session 2 / ポスターセッション 2	
P2	Breast Cancer (Perioperative) 乳腺(周術期)
Day 1 (Thu)	
Day 2 (Fri)	
Day 3 (Sat)	
Room 1	P2-1 Clinico-epidemiological data of breast cancer patients in the northwestern part of India: A Descriptive study Rajendar Byshetty (Department of surgical oncology, AIIMS-Jodhpur, India)
Room 2	P2-2 Neoadjuvant Chemotherapy plus Trastuzumab and Pertuzumab in patients with HER2-positive breast cancer Voc T. Dang (Optional Therapeutic Department, K Hospital)
Room 3	P2-3 Association between transcriptome and DCE-MRI phenotypes in invasive breast carcinoma Yanhui Zhu (Department of Breast Surgery, the First Affiliated Hospital of Nanjing Medical University)
Room 4	P2-4 Comparison of anthracycline-containing and non-anthracycline adjuvant chemotherapy regimen in stage II breast cancer Youngkyung Jeon (Oncology and Hematology Clinic, department of Internal Medicine, Pusan National University Yangsan Hospital)
Room 5	P2-5 Whole Body Positron Emission Tomography (WBPET) Scan in all patients of Breast Cancer: Is this the way forward? Abhishek Pathak (Department of Medical oncology, Command Hospital, Kolkata)
Room 6	P2-6 Neoadjuvant chemotherapy-induced change in NLR and skeletal muscle mass as prognostic markers for patients with TNBC Takaaki Oba (Division of Breast and Endocrine Surgery, Department of Surgery, Shinshu University School of Medicine) 大場 崇旦 (信州大学医学部 外科学教室 乳腺内分泌外科学分野)
Room 7	P2-7 Analysis of 150 cases of operable triple-negative breast cancer in our hospital Toru Higuchi (Breast Surgery Unit, Japanese Red Cross Satiama Hospital) 当院における手術可能なトリプルネガティブ乳がん150例の検討 樋口 徹 (さいたま赤十字病院 乳腺外科)
Room 8	P2-8 The potential of ki-67 as a prognostic and a predictive marker in triple-negative breast cancer Saori Kawai (Cancer Institute Hospital of JFCR, Breast Medical Oncology) 川井 沙織 (がん研究会有明病院 乳腺内科)
Room 9	P2-9 Postoperative breast radiotherapy using image registration of initial PET-CT before NAC Kenshiro Shiraishi (Department of Radiology, Teikyo University) 白石 憲史郎 (帝京大学 放射線科)
Room 10	P2-10 Effect of dose-dense doxorubicin and cyclophosphamide therapy (ddAC): A single-center retrospective analysis Fumie Fujisawa (Department of Medical Oncology, Osaka International Cancer Institute) 藤澤 文絵 (大阪国際がんセンター 腫瘍内科)
Room 11	
Room 12	
Room 13	
Meet the Experts	
Poster	

P2-11	The comparison of BRCA1/2 mutation rates between adjuvant Olaparib criteria and HBOC criteria for early breast cancer Yuka Endo (Department of Breast Oncology, Aichi Cancer Center Hospital) 遠藤 由香 (愛知県がんセンター 乳腺科)
P2-12	Scalp cooling can protect from chemotherapy-induced alopecia of breast cancer patients Koji Yamashita (Department of Breast Surgery, International University of Health and Welfare) 頭皮冷却による乳癌患者の化学療法に対する脱毛予防 山下 浩二 (国際医療福祉大学 乳腺外科)
P2-13	Response of Neoadjuvant Docetaxel, Trastuzumab, Pertuzumab followed by AC in HER2 positive breast cancer Hiroaki Shima (Department of Surgery, Surgical Oncology and Science) HER2陽性乳癌を対象とした術前化学療法D+Tmab+Pmab-AC逐次療法の前向き観察研究 島 宏彰 (札幌医科大学 消化器・総合、乳腺・内分泌外科)
P2-14	演題取下
P2-15	Quality of life among young women with breast cancer evidence from south india S S. katpattil (Kerala University of Health Sciences)
P2-16	Quality of Life in breast cancer patients a Population Based Study Asmin S. Shah (Kerala University of Health Sciences)
P2-17	A Retrospective Analysis of Perioperative Chemotherapy and Coronavirus Disease in Patients With Breast Cancer Kazumi Hayashi (Department of Clinical Oncology and Hematology, The Jikei University School of Medicine) 乳がんの周術期化学療法と新型コロナウイルス感染症との後方視的解析 林 和美 (東京慈恵会医科大学附属病院 腫瘍・血液内科)
11:10-11:55 Poster Session 3 / ポスターセッション 3	
P3	Rare Cancer/Cancer of Unknown Primary (Pediatric Oncology, Adolescents and Young Adults with Cancer) 希少がん・原発不明がん(小児・AYA)
P3-1	Adrenocortical Tumors in Children and Adolescents; What should We do? Hind Mohammed (Department of Pediatric Oncology, El-Mattaria Teaching Hospital)
P3-2	Role of Surgery In Pineal Region Tumours In Paediatric Population Pankaj Kumar (Dr. Ram Manohar Lohia Hospital and Postgraduate Institute of Medical Education and Research, New Delhi, India)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster

11:10-11:55 Poster Session 4 / ポスターセッション 4

P4 Rare Cancer/Cancer of Unknown Primary (Neuroendocrine tumor)
希少がん・原発不明がん(神経内分泌腫瘍)

P4-1 **A retrospective analysis of outcome of chemotherapy in extra pulmonary neuroendocrine carcinoma (EP-NEC) in our hospital**

Naoki Okubo (Department of Oncology, Yokohama City University)
大久保 直紀 (横浜市立大学附属病院 臨床腫瘍科)

P4-2 **The efficacy of combination therapy with everolimus and somatostatin analog for metastatic neuroendocrine tumor**

Kohei Ogawa (Department of Medical Oncology, Toyama Prefectural Central Hospital)
小川 浩平 (富山県立中央病院 腫瘍内科)

P4-3 **The therapeutic effect of etoposide/cisplatin continuous infusion therapy for extra-pulmonary neuroendocrine carcinoma**

Yumi Amano (Department of Medical Oncology, Kansai Electric Power Hospital)
天野 佑美 (関西電力病院 腫瘍内科)

11:10-11:55 Poster Session 5 / ポスターセッション 5

P5 Translational Research/Clinical Pharmacology (Precision Medicine 1)
TR・臨床薬理(ゲノム医療1)

P5-1 **Practice of cancer genomic profile tests at a single institution under Japanese national health insurance system**

Ippei Fukada (Genomic Medicine, The Cancer Institute Hospital of Japanese Foundation for Cancer Research)
深田 一平 (がん研究会有明病院 ゲノム診療部)

P5-2 **Comprehensive cancer genome profiling (CGP) tests at Nagoya University Hospital**

Chiaki Kondo (Department of Genome Medical Center, Nagoya University Hospital)

名大病院におけるがんゲノム中核拠点病院としての包括的がんゲノムプロファイリングの現状に関する検討

近藤 千晶 (名古屋大学医学部附属病院ゲノム医療センター)

P5-3 **Current status of cancer genome profiling using gene panel testing in Niigata University Medical & Dental Hospital**

Mae Nakano (Medical Genome Center, Niigata University Medical & Dental Hospital / Division of Digestive and General Surgery, Niigata University)

当院におけるがん遺伝子パネル検査の現状

中野 麻恵 (新潟大学歯学総合病院 がんゲノム医療センター / 新潟大学 消化器・一般外科)

P5-4 **Outcome of Comprehensive Genome Profiling (CGP) for cancer patients: Current status and issues**

Toshihiko Matsumoto (Department of Medical Oncology, Kobe City Medical Center General Hospital)

松本 俊彦 (神戸市立医療センター中央市民病院)

P5-5 **がんゲノム医療連携病院におけるがん遺伝子パネル検査実施症例の後方視的検討**

Yumi Yoshii (Department of Cancer Genomics and Medical Oncology, Nara Medical University)
吉井 由美 (奈良県立医科大学附属病院 がんゲノム・腫瘍内科)

- P5-6 **Clinical feasibility and current trends of approved multigene panels in a genomic medicine cooperative hospital**
 Nahomi Tokudome (Department of Pulmonary Medicine and Medical Oncology, Wakayama Medical University)
保険診療下でのがん遺伝子パネル検査の臨床的有用性とがんゲノム医療連携病院での現況報告
 徳留 なほみ (和歌山県立医科大学 呼吸器内科・腫瘍内科)
- P5-7 **Retrospective Study of Cases tested by FoundationOne Liquid in Yamagata University Hospital**
 Shuhei Suzuki (Department of Medical Oncology, Yamagata University)
 鈴木 修平 (山形大学 腫瘍内科)
- P5-8 **Current status and issues of cancer genome profiling tests for insurance at our hospital**
 Hidenori Kido (Department of Clinical Oncology, Graduated School of Medicine, Juntendo University)
当院における保険のがん遺伝子パネル検査の現状と課題
 城戸 秀倫 (順天堂大学医学部附属順天堂医院 腫瘍内科)
- 11:10-11:55 Poster Session 6 / ポスターセッション 6
- P6** Rare Cancer/Cancer of Unknown Primary (Case Report 1)
 希少がん・原発不明がん(ケースレポート1)
- P6-1 **A Case Report on the Diagnosis, Staging, and Management of Triple Primary Cancers of the Thyroid, Colon, and Breast**
 Jovitte Suzane G. Yalong (Department of Internal Medicine, East Avenue Medical Center)
- P6-2 **Primary hepatic Yolk sac tumor: Added to differential diagnosis of hepatic focal lesion in children**
 Ahmed Elhussain Abdelsalam (Department of Pediatric Hematology/Oncology, Children's Cancer Hospital Egypt)
- P6-3 **Exophytic and Fungating Papillary Thyroid Carcinoma: A Rare and Complex Presentation of a Well-Differentiated Malignancy**
 Harold Henrison C. Chiu (Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Philippine General Hospital)
- P6-4 **Case Report: Malignant priapism secondary to adrenal sarcoma**
 Pimchanok Tuitemwong (Department of Oncology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University)
- P6-5 **Pazopanib following irradiation achieved complete response in a PDGFRB N666K mutation positive intimal sarcoma patient**
 Akihiro Nishiyama (Division of Medical Oncology Cancer Research Institute, Kanazawa University)
 西山 明宏 (金沢大学附属病院がんセンター)
- P6-6 **Bone marrow metastasis and DIC of alveolar rhabdomyosarcoma mimicking acute leukemia**
 Ayano Sugihara (Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University)
 杉原 綾乃 (佐賀大学医学部附属病院 血液・呼吸器・腫瘍内科)

P6-7	A case of ultra high-risk gestational choriocarcinoma presented with ARDS Misao Fukuda (Department of Medical Oncology, Kameda Medical Center) 福田 美佐緒 (亀田総合病院腫瘍内科)
P6-8	A case of metastatic eyelid apocrine adenocarcinoma successfully treated with anti-androgen therapy Ryuji Hayashi (Clinical Oncology, Toyama University Hospital) 抗アンドロゲン薬が奏効した眼瞼原発転移性アポクリン腺癌の1例 林 龍二 (富山大学附属病院 臨床腫瘍部)
P6-9	Pazopanib treatment for unresectable primary intimal cardio-pulmonary angiosarcoma Shinji Hasebe (Cancer Center, Ehime University Hospital) 切除不能心肺原発血管内膜肉腫に対しパゾパニブを投与した3症例 長谷部 晋士 (愛媛大学医学部附属病院 腫瘍センター)
P6-10	Favorable response to anti-PD1 checkpoint blockade in a case of thoracic SMARCA4-deficient undifferentiated tumor Yoko Nagata (Department of Oncology Center, Hyogo College of Medicine) 長田 陽子 (兵庫医科大学がんセンター)
P6-11	The CUP bearing thoracic metastases of pathological carcinoma is a good target of IHC with anti-ALK antibody Yoriko Kato (Department of Clinical Oncology, Akita University) 胸部に転移性病変を有する原発不明癌(腺癌)はALKの免疫染色の良い対象だと思われる 加藤 和子 (秋田大学臨床腫瘍学講座)
11:10-11:55 Poster Session 7 / ポスターセッション 7	
P7	Lung Cancer/Thoracic Cancer (Prognostic factors and others) 呼吸器 (予後因子・その他)
P7-1	Overall Survival with the use of Prophylactic Cranial Irradiation in Limited Stage-SCLC: A Systematic Review Bhumika Raisinghani (Faculty of Medicine, Pelita Harapan University)
P7-2	Identification of the novel prognostic signature of genes in SCLC based on bioinformatics analysis Cheng Shi Feng (Department of Medical Oncology, Southeast University)
P7-3	Integration of ferroptosis and pyroptosis predicted overall survival of lung adenocarcinoma survival Xuyu Gu (Department of Medical Oncology, Southeast University)
P7-4	The SERPINB7, TMEM158, and SERPINE1 signature as predictor of prognosis in patients with NSCLC after vitamin C treatment Junwen Ou (Department of Oncology, Guangdong Clifford Hospital)
P7-5	Survival Improvement in NSCLC Patients with BMs Treated with BMAs Versus Non-BMAs: A Systematic Review and Meta-Analysis Amos Immanuel Chandra (Faculty of Medicine, Pelita Harapan University)
P7-6	Domestic Cooking Fuel as a Risk Factor for Lung Cancer in Women Asmin S. Shah (Kerala University of Health Sciences)

- P7-7 **Assessment of the impact of palliative care on the quality of life in advanced non small cell lung cancer patients**
S S. katpattil (Kerala University of Health Sciences)
- P7-8 **The impact of CCR8+ regulatory T cells on cytotoxic T cell function in human lung cancer**
Miya Haruna (Shionogi & Co., Ltd)
春名 美弥 (塩野義製薬株式会社)
- P7-9 **Eosinophilic pleural effusion due to lung cancer has a better prognosis than non-eosinophilic malignant pleural effusion**
Eiji Takeuchi (Department of Clinical Investigation, National Hospital Organization Kochi Hospital)
好酸球性胸水のある肺癌患者は、非好酸球性胸水の肺癌患者よりも予後が良好である
竹内 栄治 (国立病院機構高知病院臨床研究部)
- P7-10 **Development and validation of a novel prognostic nomogram for patients with giant cell carcinoma of the lung**
Feng Wang (Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University, Beijing, China)

11:10-11:55 Poster Session 8 / ポスターセッション 8

P8 COVID-19 1

- P8-1 **Risk factors on Cancer Patients and COVID-19 a Cohort study**
Moses Waiswa (Uganda Development and Health Associates)
- P8-2 **Prospective study to validate safety and efficacy of SARS-CoV-2 vaccine in patients treated with ICI or chemotherapy**
Kentarō Sawada (Division of Medical Oncology, Kushiro Rosai Hospital / Division of Internal Medicine, Kushiro Rosai Hospital)
ICIおよび化学療法を受ける患者におけるSARS-CoV-2ワクチンの安全性と有効性を検証する前向き観察研究
澤田 憲太郎 (釧路労災病院 腫瘍内科 / 釧路労災病院 内科)
- P8-3 **新型コロナウイルス感染症 (COVID-19) 流行下のがん患者の受診状況と治療方法の選択 – 頭頸部がん患者についての検討 –**
Nao Nishimura (Department of Dentistry, Osaka International Cancer Institute)
西村 奈穂 (大阪国際がんセンター 歯科)
- P8-4 **A retrospective study on the influence of COVID-19 pandemic on chemotherapy for gastrointestinal cancers**
Hiroshi Nakatsumi (Department of Gastroenterology, NHO Hokkaido Medical Center)
新型コロナウイルス感染症の流行が消化器癌薬物療法の運用に及ぼした影響についての単施設後ろ向き調査
中積 宏之 (国立病院機構北海道医療センター 消化器内科)

-
- P8-5 **Survey on the actual status of COVID-19 vaccination among cancer patients
~the result of web questionnaire~**
Hitomi Suzuki (Department of Breast Surgery)
**がん患者における新型コロナウイルス (COVID-19) ワクチン接種の実態調査
~Webアンケート結果より~**
鈴木 瞳 (一宮西病院 乳腺外科)
-
- P8-6 **A retrospective analysis of the diagnosis and management of the cancer patients
with Covid-19 like illness**
Taiji Koyama (Department of Medical Oncology/Hematology, Kobe University Hospital)
小山 泰司 (神戸大学医学部附属病院 腫瘍・血液内科)
-
- P8-7 **Impact of COVID-19 pandemic on the trigger of diagnosis with advanced thoracic
malignancies in Japan**
Akito Fukuda (Department of Thoracic Oncology, National Cancer Center Hospital)
福田 滉仁 (国立がん研究センター中央病院 呼吸器内科)
-

P9	Gastrointestinal Cancer (Esophageal Cancer 1) 消化器(食道1)
P9-1	<p>症例から学ぶ食道がん化学放射線治療後の晩発性胸膜炎・心膜炎の治療方針の検討 Takao Suzuki (Department of Medical Oncology, National Hospital Organization, Sendai Medical Center) 鈴木 貴夫 (国立病院機構 仙台医療センター 腫瘍内科)</p>
P9-2	<p>A case report of esophageal cancer with aortic dissection and gastric ulcer perforation caused by chemoradiation therapy Sakuya Koreishi (Department of Medicine and Biosystemic Science, Kyushu University) 化学放射線療法により大動脈解離および胃潰瘍穿孔をきたした高齢者食道癌の一例 是石 咲耶 (九州大学 病態修復内科学)</p>
P9-3	<p>Efficacy and safety of Nivolumab therapy for esophageal cancers Yuuki Sonoda (Department of Gastroenterology, Nagasaki University Hospital) 食道癌に対するNivolumab療法の有効性・安全性に関する検討 園田 悠紀 (長崎大学病院 消化器内科)</p>
P9-4	<p>A Retrospective Analysis of the Treatment of Esophagogastric Junction Adenocarcinoma in Our Facility Akira Tsunoda (Department of Medical Oncology, Mie University Hospital) 当院における食道胃接合部癌の治療に関する後方視的検討 角田 瑛 (三重大学医学部附属病院 腫瘍内科)</p>
P9-5	<p>An Update on the Efficacy and Safety of Nivolumab for Esophageal Squamous Cell Carcinoma: A Systematic Review Sharon Chen (Faculty of Medicine, Pelita Harapan University)</p>
P9-6	<p>Definitive chemoradiotherapy for locoregional recurrence of esophageal squamous cell carcinoma after radical surgery Kentarō Harada (Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital) 原田 健太郎 (国立がん研究センター中央病院 消化管内科)</p>
P9-7	<p>Treatment outcome following Nivolumab therapy administered after radiation therapy for esophageal cancer Fumitaka Endo (Department of Surgery, Iwate Medical University School of Medicine) 食道癌に対する放射線療法後のNivolumabの治療成績 遠藤 史隆 (岩手医科大学 外科学講座)</p>
P9-8	<p>Retrospective analysis of the safety and effectiveness of immune checkpoint inhibitors in mucosal melanoma patients Fumiyasu Hanamura (Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center) 粘膜メラノーマ患者における免疫チェックポイント阻害薬の有効性と安全性の後方視的解析 花村 文康 (九州がんセンター 消化管・腫瘍内科)</p>

P10 Gastrointestinal Cancer (Case Report 1)
消化器(ケースレポート1)

- Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Experts Poster
- P10-1 **A case of cytokine release syndrome due to immune checkpoint inhibitor and molecular targeted drug to huge hepatoma**
Seichi Yoshikawa (Gastroenterology, Nagaoka Red Cross Hospital)
巨大肝細胞癌に対する免疫チェックポイント阻害剤 (ICI) と分子標的薬 (MTD) 投与後にサイトカイン放出症候群 (CRS) を発症したと考えられた1例
吉川 成一 (長岡赤十字病院 消化器内科)
- P10-2 **Long-term survival with nivolumab and irinotecan after total gastrectomy in alpha-fetoprotein-producing gastric cancer**
Takayo Ota (Department of Medical Oncology, Izumi City General Hospital)
大田 隆代 (和泉市立総合医療センター 腫瘍内科)
- P10-3 **Clinical characteristics of pancreas cancer bearing a new non-sense mutation of *BRCA2***
Toranosuke Hattori (Department of Clinical Oncology, Akita University)
新たなBRCA2ナンセンス変異を胚細胞変異として有する膵臓癌の臨床的特徴
服部 虎之介 (秋田大学腫瘍内科)
- P10-4 **ニボルマブとイピリムマブによる病理学的完全奏功を確認した結腸癌の一例**
Hajime Ishibashi (Ibaraki Prefectural Central Hospital)
石橋 肇 (茨城県立中央病院・茨城県地域がんセンター)
- P10-5 **A case of carcinoma in situ of the pancreas preoperatively diagnosed by brushing cytology**
Takashi Seki (Department of Surgery, Meijo Hospital)
主膵管拡張を契機に擦過細胞診で術前診断しえた膵上皮内癌 (PanIN-3) の1例
関 崇 (名城病院)
- P10-6 **Report of a case of sigmoid colon cancer simultaneously harboring the *BRAF V600E* mutation and *NTRK3* fusion gene**
Kirio Kawai (Department of Medical Oncology, Kyorin University)
***NTRK3* 融合遺伝子と *BRAF V600E* 遺伝子変異を同時に有する S 状結腸癌の一例**
河合 桐男 (杏林大学医学部腫瘍内科)
- P10-7 **A Case of Gastric Cancer with IrAE Caused by Nivolumab and Survived for 2 Years and 3 Months without Progression**
Itaru Satou (Department of Medical Oncology, Ageo Central General Hospital)
NivolumabによるirAE (心筋炎) を発症し2年3か月無治療で無増悪生存中の進行胃癌の一例
佐藤 到 (上尾中央総合病院 腫瘍内科)
- P10-8 **当院における根治切除不能進行再発食道癌に対するNivolumabの治療経験**
Daisuke Kobayashi (Department of Gastroenterological Surgery, Komaki City Hospital)
小林 大介 (小牧市民病院 消化器外科)
- P10-9 **A case of colorectal cancer with numb chin syndrome as the first symptom**
Atsuko Kakiyama (Digestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences)
Numb chin syndromeを初発症状とした大腸癌の1例
柿原 敦子 (鹿児島大学大学院医歯学総合研究科 消化器疾患・生活習慣病学分野)

P10-10	<p>Encorafenib+Binimetinib+Cetuximab併用療法中に網膜漿膜下浮腫をきたしたBRAF V600E変異陽性上行結腸癌の一例</p> <p>Sachiko Seki (Tokyo Saiseikai Central Hospital) 関 彩千子 (東京都済生会中央病院)</p>	Day 1 (Thu)
P10-11	<p>Encorafenib plus binimetinib for BRAF V600E mutation-positive colon cancer in case of cetuximab hypersensitivity</p> <p>Yoshiaki Mihara (Department of Medical Oncology, Saitama Medical University International Medical Center)</p> <p>Cetuximab過敏症のBRAF V600E変異陽性切除不能大腸癌に対しencorafenibとbinimetinibの併用療法が有効であった一例</p> <p>三原 良明 (埼玉医科大学国際医療センター 腫瘍内科)</p>	Day 2 (Fri)
P10-12	<p>FOLFOX+Trastuzumab therapy for HER2-positive gastric cancer with bone marrow carcinomatosis</p> <p>Shohei Ueno (Department of Hematology/Oncology, Japan Community Healthcare Organization Kyushu Hospital / Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences)</p> <p>骨髄癌腫症を伴うHER2陽性胃癌にFOLFOX + Trastuzumab療法を施行した一例</p> <p>上野 翔平 (独立行政法人 地域医療機能推進機構 九州病院 血液・腫瘍内科/九州大学大学院 医学研究院 病態修復内科学)</p>	Day 3 (Sat)
11:10-11:55 Poster Session 11 / ポスターセッション 11		
P11	Hepatobiliary/Pancreatic Cancer (HCC) 肝胆腫(HCC)	Room 1
P11-1	<p>Chemotherapy for recurrent hepatocellular carcinoma after liver transplantation: A case report</p> <p>Hidekazu Kuramochi (Department of Chemotherapy and Palliative Care, Tokyo Women's Medical University) 倉持 英和 (東京女子医科大学病院 化学療法・緩和ケア科)</p>	Room 2
P11-2	<p>A case of combined hepatocellular-cholangiocarcinoma successfully treated with Atezolizumab plus Bevacizumab</p> <p>Takafumi Kitazono (Department of Hematology and Oncology, Japan Community Health Care Organization Kyushu Hospital)</p> <p>アテゾリズマブ+ベバシズマブ療法が奏効した肉腫様変化を伴う混合型肝癌の一例</p> <p>北園 貴史 (地域医療機能推進機構 九州病院 血液腫瘍内科)</p>	Room 3
P11-3	<p>Exploration of Deficient Mismatch Repair (dMMR)-Related Somatic Mutation Signature in Multistage Liver Carcinogenesis</p> <p>Haruhiko Takeda (Department of Gastroenterology and Hepatology, Kyoto University) 竹田 治彦 (京都大学消化器内科)</p>	Room 4
P11-4	<p>Efficacy and safety of cabozantinib in patients with advanced hepatocellular carcinoma: a retrospective analysis</p> <p>Taku Sawafuji (University of Tsukuba Hospital) 澤藤 拓 (筑波大学附属病院)</p>	Room 5
P11-5	<p>Case report: Responses to immunotherapy as a first line treatment of metastatic liver cancer</p> <p>Hang Thu Hoang (Department of Optimal Clinical Care, National Cancer Hospital Vietnam)</p>	Room 6

P11-6 **Efficacy and Safety of Lenvatinib in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation**
Kyunghye Bang (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine)

P11-7 **Efficacy and safety of atezolizumab plus bevacizumab treatment in patients with unresectable hepatocellular carcinoma**
Yoshimi Fujishima (Department of Medical Oncology, Kobe Minimal Invasive Cancer Center)
藤島 佳未 (神戸低侵襲がん医療センター 腫瘍内科)

P11-8 **HDV viral load related liver fibrosis patients clinical evaluation based on M2BPGI level in serum**
Lkhagvaochir Tovuu (Department of Laboratory Medicine, National Cancer Center of Mongolia)

P11-9 **Multimodality treatment of hepatoblastoma & Its Outcome- A tertiary centre experience**
Nikhil Garg (Department of Surgical Oncology, AIIMS Bathinda, India)

P11-10 **Atezolizumab + bevacizumab combination therapy for advanced hepatocellular carcinoma in our hospital**
Atsushi Naganuma (Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center)

当院の進行肝細胞癌に対するアテゾリズマブ+ベバシズマブ併用療法の治療成績
長沼 篤 (国立病院機構 高崎総合医療センター 消化器内科)

P11-11 **Individualizing prediction model for 3-year risk of liver cancer in chronic hepatitis B carriers**
Maomao Cao (National Cancer Center)

11:10-11:55 Poster Session 12 / ポスターセッション 12

P12 Breast Cancer (Cases)
乳腺(ケースシリーズ・ケースレポート)

P12-1 **Rapid & Fulminant progression of advanced breast cancer following withdrawal of CDK inhibitors: Interesting case report**
Chaturbhuj Agrawal (Consultant Medical Oncology, RGCI, New Delhi)

P12-2 **Rare cases of metastatic breast cancer with gastric mucosal metastases: Series of two cases**
Silky Kothiwala (Department of Gynecology, Bhagwati Hospital, Rohini Sector 9, New Delhi)

P12-3 **A retrospective study of trastuzumab deruxtecan therapy in patients with metastatic HER2-positive breast cancer**
Kanako Saito (Department of Medical Oncology, Mie University Hospital)

転移再発HER2陽性乳癌に対するTrastuzumab deruxtecan療法の後方視的検討
斎藤 佳菜子 (三重大学医学部附属病院 腫瘍内科)

P12-4 **A case of HER2-positive breast cancer associated with systemic sarcoidosis**
Yuurin Kondou (Department of Chemotherapy and Palliative Care, Tokyo Women's Medical University)
近藤 侑鈴 (東京女子医科大学 化学療法・緩和ケア科)

- P12-5 **Orbital metastasis from breast cancer: case report and review of the literature**
Eiko Inamasu (Department of Surgery, Sasebo Central Hospital)
乳癌の眼窩転移：症例と過去の報告
稲益 英子 (佐世保中央病院 外科)
- P12-6 **A case report of cutaneous metastasis in patient with melanoma and recurrent breast cancer**
Alisara Srinilta (Department of Breast Surgery, Namarak Hospital)
- P12-7 **Nodular Regenerative Hyperplasia Induced by Trastuzumab Emtansine**
Eiko Sakata (Department of Breast Surgery, Niigata City General Hospital)
トラスツズマブエムタンシン治療により結節性再生成過形成を生じた一例
坂田 英子 (新潟市民病院 乳腺外科)
- P12-8 **Three cases of breast cancer with respiratory insufficiency who continued outpatient care with the support of HOT**
Shoko Akiyama (Department of Medical Oncology, Sendai Medical Center)
在宅酸素療法(HOT)を導入し外来治療を継続した呼吸不全を伴う乳癌の3例
秋山 聖子 (仙台医療センター 腫瘍内科)
- P12-9 **The sort-time results of the comprehensive genomic profiling tests for metastatic breast cancer at a single institute**
Mayako Terao (Departments of Breast Oncology, Tokai University School of Medicine)
当院において遺伝子パネル検査を施行した乳癌7症例の報告
寺尾 まやこ (東海大学医学部 外科学系 乳腺・腫瘍科学)
- P12-10 **A case of drug-induced interstitial pneumonia caused by trastuzumab delxtecan**
Yui Horie (Breast Oncology, Tokai University)
トラスツズマブデルクスステカンにより薬剤性間質性肺炎を生じた1例
堀江 祐以 (東海大学医学部付属病院 乳腺外科)
- P12-11 **Efficacy of trastuzumab deruxtecan for HER2-positive breast and gastric cancer with brain metastases: two case reports**
Taro Mizuno (Department of Medical Oncology, Nagoya Medical Center)
水野 太朗 (名古屋医療センター 腫瘍内科)

11:10-11:55 Poster Session 13 / ポスターセッション 13

P13 Genitourinary Cancer (Urinary tract Cancer)
泌尿器 (尿路上皮がん)

- P13-1 **KEYNOTE-905/EV-303: Perioperative Pembrolizumab or Pembrolizumab + Enfortumab Vedotin for Muscle-Invasive Bladder Cancer**
Andrea Necchi (IRCCS San Raffaele Hospital and Scientific Institute)
- P13-2 **KEYNOTE-992: Pembrolizumab (pembro)+Chemoradiotherapy (CRT) Versus Placebo+CRT for Muscle-Invasive Bladder Cancer (MIBC)**
Nicholas D. James (Institute of Cancer Research, The Royal Marsden Hospital NHS Foundation Trust)
- P13-3 **Long-term efficacy of neoadjuvant chemotherapy in muscle invasive urothelial cancer - A retrospective study**
Shahid Mahmood (Medical oncology, Canberra Hospital, ACT, Australia)

P13-4	演題取下
P13-5	転移進行尿路上皮癌に対する一次治療としてのNedaplatin (NDP)の有用性 Riku Ino (Department of Medical Oncology, Kameda General Hospital) 猪野 陸 (亀田総合病院 腫瘍内科)
11:10-11:55 Poster Session 14 / ポスターセッション 14	
P14	Genitourinary Cancer (Case Report) 泌尿器(ケースレポート)
P14-1	難治性精巣腫瘍に対しTIP療法の再投与が著効した一例 Soichiro Shimura (Department of Urology, Kitasato University School of Medicine) 志村 壮一郎 (北里大学病院 泌尿器科)
P14-2	High grade urothelial carcinoma with gastrocnemius muscle metastases Marfuah Nik Eezamuddeen (Department of Radiotherapy and Oncology, University Kebangsaan Malaysia (UKM) Medical Centre)
P14-3	When is the optimal time for comprehensive genome profile analysis in patients with advanced urothelial carcinoma? Tomoyuki Makino (Department of Urology, Ishikawa Prefectural Central Hospital) 牧野 友幸 (石川県立中央病院 泌尿器科)
P14-4	A case of renal pelvic cancer treated with afatinib after reconsidering pathological diagnosis based on findings of CGP Takumi Fujiwara (Department of Genomic Medicine, Graduate School of Medicine, Mie University / Department of Pulmonary and Critical Care Medicine, Graduate School of Medicine, Mie University) 包括的がんゲノムプロファイル検査を契機として診断を変更し、アファチニブを投与した腎盂がんの1例 藤原 拓海 (三重大学医学部附属病院 ゲノム診療科 / 三重大学医学部附属病院 呼吸器内科)
P14-5	A case of pembrolizumab-induced gastric ulcer as immune-related adverse events Kei Terasaki (Department of Gastroenterology and Hepatology, Saiseikai Suita Hospital) ペムブロリズマブによって引き起こされた免疫関連有害事象としての胃潰瘍の一例 寺崎 慶 (大阪府済生会吹田病院消化器内科)
P14-6	転移性腎癌に対し、ニボルマブ+イピリムマブ療法を初回投与後、高度の全身浮腫、腎機能低下を認めた1例 Yuta Takezawa (Urology, Toyama Prefectural Central Hospital) 武澤 雄太 (富山県立中央病院 泌尿器科)
P14-7	A Case of Remarkable Therapeutic Response to Olaparib Treatment for Castration-Resistant Prostate Cancer Takeshi Ujike (Department of Urology, Osaka Rosai Hospital) 去勢抵抗性前立腺癌に対しオラパリブ治療が著効を示した1例 氏家 剛 (大阪労災病院泌尿器科)

P14-8 **Cancer of unknown primary diagnosed with poorly differentiated prostate cancer, eventually: A case report**
Kazutaka Iijima (Department of Medical Oncology, Tonan Hospital)
原発不明癌として精査し確定診断に至った低分化型前立腺癌の1例
飯島 一飛 (斗南病院 腫瘍内科)

11:10-11:55 Poster Session 15 / ポスターセッション 15

- P15** Multidisciplinary Team Program (AE)
多職種連携プログラム (副作用)
- P15-1 **サージカルグローブを用いた化学療法起因性末梢神経障害予防の圧迫療法の運用
—多職種協働による実践—**
Fumiko Imamichi (Kobe City Medical Center General Hospital)
今道 富美子 (神戸市立医療センター中央市民病院 看護部)
- P15-2 **Monitoring of Serious Adverse Events in Oncology; The Reality in the Real-World**
Hideki Tsujimura (Division of Medical Oncology, Chiba Cancer Center)
がん薬物療法中の重篤な有害事象 (SAE) ; リアルワールドで見えたこと
辻村 秀樹 (千葉県がんセンター 外来化学療法科)
- P15-3 **当院におけるirAEの発現状況**
Shiori Saito (Saiseikai Senri Hospital)
西塔 志織 (大阪府済生会千里病院)
- P15-4 **消化管間質性腫瘍患者におけるイマチニブ単剤療法の投与状況および副作用に関する実態調査**
Yukana Tomoda (Department of Pharmacy, National Cancer Center Hospital)
友田 有加葉 (国立がん研究センター中央病院 薬剤部)
- P15-5 **Retrospective study for the incidence and risk factors of fluid retention due to Ramucirumab in colorectal cancer**
Kazuyo Miyagi (Department of Pharmacy, National Hospital Organization Osaka National Hospital)
切除不能大腸癌におけるラムシルマブによる体液貯留の発現状況とリスク因子の検討
宮城 和代 (独立行政法人 国立病院機構 大阪医療センター 薬剤部)

Day 1 (Thu)

Day 2 (Fri)

Day 3 (Sat)

Room 1

Room 2

Room 3

Room 4

Room 5

Room 6

Room 7

Room 8

Room 9

Room 10

Room 11

Room 12

Room 13

Meet the
Experts

Poster

ポスター会場 (国立京都国際会館 1階 ニューホール)

18:00-18:45 Poster Session 16 / ポスターセッション 16

P16 Hepatobiliary/Pancreatic Cancer (Gallbladder and Biliary Tract Cancer)
肝胆膵(胆嚢・胆道)

P16-1 **A clinical analysis of f advanced biliary tract cancers : single-institution outcomes**
Toru Otsuru (Department of Frontier Science for Cancer and Chemotherapy Osaka University Graduate School of Medicine)
大鶴 徹 (大阪大学大学院医学系研究科 消化器外科 先進薬物療法開発学)

P16-2 **A retrospective analysis of pembrolizumab in patients with high microsatellite instability cholangiocarcinoma**
Takehiro Shimizu (Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine)

MSI-high胆道癌に対するペムブロリズマブの後方視的分析
清水 雄大 (群馬大学大学院医学系研究科 消化器・肝臓内科学)

18:00-18:45 Poster Session 17 / ポスターセッション 17

P17 Hepatobiliary/Pancreatic Cancer (Pancreatic Cancer-Miscellaneous 1)
肝胆膵(膵臓-その他1)

P17-1 **A case of pancreatic cancer after treatment of acute pancreatitis , underwent chemotherapy with complete response**
Takahiro Kamiga (Department of Surgery, Sendai Tokushukai Hospital)
急性膵炎後の膵癌に対して化学療法を施行して完全奏効となった1例
神賀 貴大 (仙台徳洲会病院 外科)

P17-2 **Three cases of PanIN found in dilated pancreatic ducts**
Hiroyuki Kato (Department of Gastroenterological Surgery Fujita Health University School of Medicine Bantane Hospital)
膵管拡張で発見されたPanINの3例
加藤 宏之 (藤田医科大学 ばんだね病院 消化器外科)

P17-3 **A case of advanced pancreatic cancer with PALB2 germline mutation for which platinum was highly effective**
Yu Chen (Department of Medical Oncology, Hirosaki University)
PLAB2 germline mutationを認めた切除不能膵癌に対して、プラチナ系が著効した1例
陳 豫 (弘前大学医学部附属病院 腫瘍内科)

P17-4 **Association between family history of HRD-related malignancies and response to oxaliplatin in pancreatic cancer**
Yurie Tokito (Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo)
時任 佑里恵 (東京大学医学部附属病院 消化器内科)

- P17-5 **Early onset of anorexia-cachexia related worsening of cachexia symptoms during chemotherapy for pancreatic cancer**
 Shuichi Mitsunaga (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East / Division of Biomarker Discovery, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center)
 光永 修一 (国立がん研究センター東病院 肝胆膵内科/国立がん研究センター 先端医療開発センター バイオマーカー探索TR分野)
- P17-6 **Fibrinogen to Albumin Ratio Predicts Prognosis in Pancreatic Cancer Patients: A Systematic Review and Meta-Analysis**
 Alexander E. Purnomo (Faculty of Medicine, Pelita Harapan University)
- P17-7 **Clinical utility of comprehensive genome profiling in pancreatic cancer**
 Tomohiro Kubo (Department of Medical Oncology, Sapporo Medical University School of Medicine)
 久保 智洋 (札幌医科大学医学部 腫瘍内科学講座)

18:00-18:45 Poster Session 18 / ポスターセッション 18

- P18** Hematologic Malignancies (Case Report)
 血液(ケースレポート)
- P18-1 **Good controlled chylothorax by single thoracic drainage and a lipid-limited diet in Malignant lymphoma**
 Shigeru Sasaki (Saitama-Ken Saiseikai Kawaguchi General Hospital, Department of Medical Oncology)
両側乳び胸水が単回の胸腔穿刺と低脂肪食管理によりコントロール可能になった悪性リンパ腫症例
 佐々木 滋 (埼玉県済生会川口総合病院 腫瘍内科)
- P18-2 **A case of ATLL with HTLV-1-infected HRS-like cells, successfully treated with allogeneic stem cell transplantation**
 Yuto Hibino (Department of Hematology and Medical Oncology, Kanagawa Cancer Center)
HRS様細胞を伴う成人T細胞白血病/リンパ腫に対して同種造血幹細胞移植を施行した一例
 日比野 勇人 (神奈川県立がんセンター 血液・腫瘍内科)
- P18-3 **Lenalidomide plus rituximab regimen for anti-CD20 monoclonal antibody refractory indolent lymphoma: 6 case series**
 Rie Ito (Department of Hematology and Oncology, Toyohashi Municipal Hospital)
抗CD20モノクローナル抗体抵抗性の低悪性度リンパ腫に対するレナリドミド+リツキシマブ療法:6症例の検討
 伊藤 理恵 (豊橋市民病院 血液・腫瘍内科)
- P18-4 **Chronic myeloid leukemia with a coexistence of *BCR-ABL1* and *CALR* mutation**
 Rie Shimizu (Department of Hematology and Oncology)
***BCR-ABL1*融合遺伝子と*CALR*遺伝子変異を共発現した慢性骨髄性白血病**
 清水 里恵 (公立陶生病院 血液・腫瘍内科)
- P18-5 **Therapy-related myelodysplastic syndrome harboring inv(3) (q21q26.2): a case report**
 Masahiro Manabe (Osaka General Hospital of West Japan Railway Company)
染色体異常 inv(3) (q21q26.2) を伴った治療関連骨髄異形成症候群症例
 間部 賢寛 (西日本旅客鉄道株式会社 大阪鉄道病院)

Day 1 (Thu)	P18-6	Two cases of secondary acute lymphoblastic leukemia Masayo Yamamoto (Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology/Oncology, Department of Medicine, Asahikawa Medical University) 当科で経験した二次性急性リンパ性白血病の2例 山本 昌代 (旭川医科大学 内科学講座 病態代謝・消化器・血液腫瘍制御内科学分野)
Day 2 (Fri)	18:00-18:45 Poster Session 19 / ポスターセッション 19	
Day 3 (Sat)	P19	Breast Cancer (Survivorship and awareness) 乳腺 (サバイバーシップ・アウェアネス)
Room 1	P19-1	Breast self-examination and breast cancer awareness of women in Bangladesh Mahmuda Khatun (Biochemistry and Molecular Biology, MBSTU, Mawlana Bhashani Science and Technology University)
Room 2	P19-2	Association of resistin and risk of breast cancer among postmenopausal women: A meta-analytic synthesis Md Azharuddin (School of Pharmaceutical Education and Research, Jamia Hamdard)
Room 3	P19-3	Relationship of knowledge level with ability of breast examination in preventing breast cancer in WCDC 2021 participants Putu Gangga Pusphita Dewi (Udayana University)
Room 4	P19-4	A Cross-Sectional Study and Awareness of Breast Self-Examination of Bangladeshi Women at Dhaka Medical College Hospital Farzana Sultana (Department of Gynecology and Obstetrics, Jahurul Islam Medical College)
Room 5	P19-5	Awareness about BSE, Early Breast Cancer Detection Among Patients attending BSMMU and NICRH Hospital in Bangladesh Md Shariful Islam (University of Kentucky, USA / Dept. of Biotechnology and Genetic Engineering, Mawlana Bhashani Science and Technology University, Santosh, Tangail- 1902, Bangladesh / Scientific Officer, RT-PCR Lab, Japan Medical and Research Center BD 3, Ga-99/3/ A & B, Manama MS Toren, Progoti Sharani, Middle Badda; Bangladesh)
Room 6	18:00-18:45 Poster Session 20 / ポスターセッション 20	
Room 7	P20	Translational Research/Clinical Pharmacology (Basic science, Biomarker) TR・臨床薬理 (基礎研究・バイオマーカー)
Room 8	P20-1	Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence Kazuto Nishio (Department of Genome Biology, Kindai University Faculty of Medicine) 西尾 和人 (近畿大学医学部ゲノム生物学)
Room 9	P20-2	Observational study to evaluate RAS status in ctDNA for mCRC patients with RAS mutant tumor: RASMEX study (JACCRO CC-17) Naoki Izawa (Department of Medical Oncology, St. Marianna University School of Medicine) 伊澤 直樹 (聖マリアンナ医科大学 臨床腫瘍学)
Room 10	P20-3	DNMT3B contributes to the organoid-formation ability of colorectal-cancer cells derived from patients Ryosuke Taguchi (Department of Medicine and Biosystemic Science, Kyushu University) 田口 綾祐 (九州大学病態修復内科)
Room 11	Meet the Experts	
Room 12	Poster	

P20-4	Autophagy associated circulatory HMGB-1 as a potent non-invasive marker for diagnosis of Urothelial Carcinoma of Bladder Alpana Sharma (Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India)
P20-5	Usefulness of cytology cell pellet for the Amoy 9-in-1 assay Hiroaki Kodama (Division of Thoracic Oncology, Shizuoka Cancer Center) 児玉 裕章 (静岡県立静岡がんセンター 呼吸器内科)
P20-6	An automatic LC-MS/MS method for the routine measurement of 12 kinase inhibitor Daisuke Amenomiya (Department of Pharmacy, National Cancer Center Hospital) 雨宮 大介 (国立研究開発法人 国立がん研究センター 薬剤部)
P20-7	Quantitation of ramucirumab concentration by LC-MS/MS with nSMOL method and pharmacokinetics in NSCLC patients Kazumasa Akagi (Division of Molecular Pharmacology, National Cancer Center Research Institute) 赤城 和優 (国立がん研究センター研究所 分子薬理研究分野)
P20-8	Exploratory research on biomarkers for treatment response of paclitaxel Satoru Yamaga (Department of Medical and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan) 山家 寛 (九州大学大学院医学研究院病態修復内科学)
P20-9	Eribulin for breast cancer cells with resistance to endocrine therapy promotes re-expression of estrogen receptor Wataru Goto (Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine) 後藤 航 (大阪市立大学大学院医学研究科 乳腺内分泌外科)
18:00-18:45 Poster Session 21 / ポスターセッション 21	
P21	Palliative Care/Symptom Management 1 緩和ケア・支持療法1
P21-1	The herbal treatment of Covid 19 proved to be boon for cancer patients a observational cross sectional study Jitendra Acharya (Department of Dentistry and Palliative Care Medicine)
P21-2	Patient Satisfaction with Communication in Cancer Care in Public and Private Hospitals in Russia Maxim Kotov (NMRC of Oncology named after N.N.Petrov of MoH of Russia)
P21-3	Clinical application of small fractionated hyperthermia combined with natural plant drugs for advanced cancer Pu Rong (Department of Medical Oncology, Fuxing Hospital)
P21-4	The effectiveness of digital interventions on reducing fear of cancer recurrence: A systematic review and meta-analysis Nutthaporn Chandeying (Department of Obstetrics and Gynecology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Thailand)
P21-5	Predicting tolerability of high-dose fentanyl buccal tablets in cancer patients Dong-Hoe Koo (Division of Hematology/Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine)

- P21-6 Outcome of palliative endotracheal tube withdrawal in terminal illness patient with or without cancer**
Supachat Chompoonuch (Department of Medicine, Bhumibol Adulyadej Hospital, Royal Thai Air Force, Thailand)
-
- P21-7 Concordance study of between IBM Watson for genomics and real clinical practice for solid cancer**
Jong Gwon Choi (Konyang University Hospital)
-
- P21-8 Anxiety and depression among cancer patients and family caregivers at the Philippine General Hospital Cancer Institute**
Harold nathan Tan (Division of Medical Oncology, University of the Philippines - Philippine General Hospital)
-
- P21-9 The pain experience among cancer patients at the Philippine General Hospital Cancer Institute**
Harold nathan Tan (Division of Medical Oncology, University of the Philippines - Philippine General Hospital)
-
- P21-10 Family factors influencing choice of final-month care place for end-of-life cancer patients: A preliminary study**
Eriko Hayashi (Nursing Course, School of Medicine, Yokohama City University)
終末期のがん患者とその家族が最期の療養の場の決定に影響を与える要因：予備的研究
林 ぬり子 (横浜市立大学 医学部 看護学科 成人看護領域)
-
- P21-11 Effect of Olanzapine (2.5mg vs. 5mg) as prevention of highly emetogenic chemotherapy-induced nausea and vomiting**
Yasuko Takeda (Department of Pharmacy, National Cancer Center Hospital)
竹田 靖子 (国立がん研究センター中央病院薬剤部)
-
- P21-12 Existence of dehydration in outpatient cancer chemotherapy**
Michio Inukai (Department of Internal Medicine, Cancer Chemotherapy Center, Okayama Saiseikai General Hospital)
外来がん化学療法における脱水症の危険性
犬飼 道雄 (岡山済生会総合病院 内科・がん化学療法センター)
-
- P21-13 A retrospective study of impact of cancer rehabilitation on physical and nutritional condition in cancer patients**
Takashi Imajima (Sasebo Kyosai Hospital)
今嶋 克志 (佐世保共済病院)
-
- P21-14 Evaluation of the efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy**
Rio Honma (Department of Medical Oncology, Tonan Hospital)
化学療法誘発性末梢神経障害に対するミロガバリンの有効性と安全性の検討
本間 理央 (国家公務員共済組合連合会 斗南病院 腫瘍内科)
-
- P21-15 Feasibility of a nurse-initiated CBI program for symptom clusters in advanced NSCLC patients - a qualitative study**
Tamami Hamada (Department of Nursing, Asahikawa Medical University)
進行非小細胞肺がん患者における症状クラスターのための看護師主導認知行動療法介入の実用性一質的研究
濱田 珠美 (旭川医科大学医学部看護学科)

P21-16 **Olanzapine in secondary prevention for chemotherapy-induced nausea and vomiting: a retrospective real-world study**
Haruka Kono (Junior Resident, Tokyo Rinkai Hospital)
河野 遼 (東京臨海病院 臨床研修医)

P21-17 **Safety and effectiveness of mirogabalin for CIPN induced by nab-paclitaxel in patients with pancreatic cancer**
Kei Saito (Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo)
膵癌化学療法患者のナブパクリタキセルによるCIPNに対するミロガバリンベシル酸塩の安全性と有効性
齋藤 圭 (東京大学医学部附属病院 消化器内科)

18:00-18:45 Poster Session 22 / ポスターセッション 22

P22 Multidisciplinary Team Program (Logistics and education)
多職種連携プログラム(運用・教育)

P22-1 **The Clinical effect of the clinical pathways by the development and the management in the chemotherapeutic treatment**
Emi Nakata (Miyazaki Prefectural Miyazaki Hospital)
がん薬物療法におけるクリニカルパス作成と運用の効果
仲田 恵美 (宮崎県立宮崎病院看護部)

P22-2 **がん薬物療法支援チーム設立と取り組みについて**
Tomoaki Miyata (Department of Pharmacy, Saku Central Hospital Advanced Care Center)
宮田 智陽 (佐久医療センター 薬剤部)

P22-3 **当院の院内がんボードの現状**
Masaya Inoue (Department of Medical Oncology, Shimane University Hospital)
井上 政弥 (鳥根大学医学部附属病院 腫瘍内科)

P22-4 **Regional cooperation and medical cooperation for young patient with acute leukemia with cerebral infarction**
Hitomi Tanoue (Kumamoto Red Cross Hospital)
脳梗塞を合併した急性骨髄性白血病の若年患者の医療連携と地域連携
田上 ひとみ (熊本赤十字病院 看護部)

P22-5 **Meanings and Problems of National Cancer Registration in a General Hospital**
Kan Kato (Department of Internal Medicine, Tokyo Kensei Hospital / Department of Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital)
一般病院における全国がん登録の意義と課題
加藤 冠 (東京健生病院 内科 / がん・感染症センター都立駒込病院 呼吸器内科)

P22-6 **Development of a self-check program for improvement in quality of care in outpatient chemotherapy centers**
Yoshimasa Saito (Institute for Cancer Control, National Cancer Center / Department of Pharmacy, National Cancer Center Hospital)
外来化学療法室の質向上を支援するためのセルフチェックプログラムの開発
齋藤 義正 (国立がん研究センターがん対策研究所 / 国立がん研究センター中央病院薬剤部)

P22-7 **The effectiveness of Hybrid learning mode (Virtual Environment and Ann setup) in radiotherapy education**
Eva Y W Cheung (School of Medical and Health Sciences, Tung Wah College, Hong Kong)

18:00-18:45 Poster Session 23 / ポスターセッション 23

P23 Multidisciplinary Team Program (Interdisciplinary Approach to Cancer Care)
多職種連携プログラム (チーム医療)

P23-1 **Describing oncology visits to a tertiary care emergency department A pilot project**
Thomas T. Huynh (College of Pharmacy, Dalhousie University / Nova Scotia Health Authority)

P23-2 **外来化学療法室におけるリツキシマブ投与時間短縮レジメン導入前後の益と害の実態調査**
Akemi Awatsu (Department of Nursing, Hirosaki University Hospital)
栗津 朱美 (弘前大学医学部附属病院 看護部)

P23-3 **An outpatient receiving chemotherapy follow-up using ePRO (electronic Patient Reported Outcome)-CTCAE**

Yoshihiro Naiki (Department of Pharmacy, Ina Central Hospital / Department of Pharmacy, National Hospital Organization Matsumoto Medical Center)

ePRO-CTCAEで外来がん薬物療法の有害事象をフォローアップした1例
内木 義泰 (伊那中央病院 薬剤部 / 国立病院機構 まつもと医療センター薬剤部)

P23-4 **診療科・職種横断的ICI (Immune Checkpoint Inhibitor) チーム介入の現状と課題**
Atsuko Tsukahara (National Center for Global Health and Medicine)
塚原 敦子 (国立国際医療研究センター病院)

P23-5 **Development and utilization of medical questionnaire by immune checkpoint inhibitor team**

Ayumi Tsuchiya (Pharmaceutical Department, Center Hospital of the National Center for Global Health and Medicine)

免疫チェックポイント阻害薬チームにおける外来診察前問診票の取り組み
土屋 亜祐美 (国立国際医療研究センター病院 薬剤部)

P23-6 **多職種介入による神経内分泌腫瘍に対するルテチウムオキソドトロチドによるペプチド受容体放射線核種療法 (PRRT) 導入**

Kazuhiro Yanagihara (Department of Medical Oncology, Kansai Electric Power Hospital)
柳原 一広 (関西電力病院 腫瘍内科)

P23-7 **The symptom monitoring system using Xeloda application in adjuvant chemotherapy for colon cancer: A pilot study**

Yoshinori Kikuchi (Department of Clinical Oncology, Faculty of Medicine, Toho University)

大腸癌術後補助化学療法でのゼロダアプリを用いた症状モニタリング：パイロット研究
菊池 由宣 (東邦大学医学部臨床腫瘍学講座)

P23-8 **Difficulties certified nurses and nurse specialists felt in providing nursing care to outpatients with bone metastasis**

Kyoko Takayama (Faculty of Health Care and Nursing, Juntendo University)

骨転移を有する外来がん患者に療養支援を行う上で専門看護師・認定看護師が抱く困難感
高山 京子 (順天堂大学 医療看護学部)

P23-9 **Construction of a model for palliative care education for visiting nurses involved with patients with intractable cancer**
 Masako Nakamura (Department of Nursing, Aichi Medical University)
訪問看護師に対する難治性がん患者への緩和ケア教育を継続的に促進するためのモデルの構築
 中村 正子 (愛知医科大学 看護学部)

18:00-18:45 Poster Session 24 / ポスターセッション 24

P24 Multidisciplinary Team Program (Miscellaneous)
 多職種連携プログラム(その他)

P24-1 **Machine Learning Identification of Bronchogenic Carcinoma based on Fuzzy Logic**
 Rifaldy Fajar (Applied and Interdisciplinary Mathematics (InterMaths) Master Program, University of L'Aquila)

P24-2 **Machine Learning Classification of Colorectal Cancer Stage based on Recurrent Neural Network Model Algorithm**
 Rifaldy Fajar (Applied and Interdisciplinary Mathematics (InterMaths) Master Program, University of L'Aquila)

P24-3 **Interdisciplinary Approach to Breast Cancer Care in Bangladesh perspectives: Recent scenario**
 Md Shariful Islam (University of kentucky, USA)

18:00-18:45 Poster Session 25 / ポスターセッション 25

P25 Cross-sectional Program (Genome)
 臓器横断プログラム(ゲノム)

P25-1 **当院のがん遺伝子パネル検査における遺伝カウンセリングの現状について**
 Maiko Nishida (Department of Surgery, Japanese Red Cross Society Kyoto Daini Hospital)
 西田 真衣子 (京都第二赤十字病院 外科)

P25-2 **Current status and issues of cancer gene panel testing at our hospital**
 Hiroyuki Sakashita (Department of Cancer Genome Center, Yokosuka Kyosai Hospital)
当院におけるがん遺伝子パネル検査の現状と課題
 坂下 博之 (横須賀共済病院 がんゲノムセンター)

P25-3 **Perceptions of comprehensive genomic profiling (CGP) among patients and families undergoing CGP : a retrospective study**
 Misaki Takeno (Department of Pharmacy, National Cancer Center Hospital East)
がん遺伝子パネル検査 (CGP) を受ける患者とその家族のCGPに関する認識についての診療録調査
 竹野(小林) 美沙樹 (国立がん研究センター東病院 薬剤部)

P25-4 **A family with male breast cancer, with BRCA1 pathogenic variant**
 Ichiko Yamakita (Department of Cancer Genome & Clinical Oncology, Hiroshima City Asa Citizens Hospital)

BRCA1病的バリエントを認めた男性乳がんの1家系
 山北 伊知子 (広島市立安佐市民病院 がんゲノム診療科 兼 腫瘍内科)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Meet the Poster Experts

P25-5

Effective treatment of chemotherapy with EGFR Ab for an unresectable Lynch syndrome-associated small intestinal cancer

Atsushi Toyofuku (Department of Surgery, Kitayushu General Hospital)

抗EGFR抗体併用化学療法が著効したLynch症候群関連小腸癌の1例

豊福 篤志 (北九州総合病院 総合外科)

Day 1 (Thu)

Day 2 (Fri)

Day 3 (Sat)

Room 1

Room 2

Room 3

Room 4

Room 5

Room 6

Room 7

Room 8

Room 9

Room 10

Room 11

Room 12

Room 13

Meet the Experts

Poster

ポスター会場 (国立京都国際会館 1階 イベントホール)

18:00-18:45 Poster Session 26 / ポスターセッション 26

P26	Gastrointestinal Cancer (Gastric Cancer 1) 消化器(胃1)
P26-1	Retrospective Study of FOLFOX in Advance Gastric Cancer Patients Takumi Ito (Department of Medical Oncology, Ishikawa Prefectural Central Hospital) 伊藤 拓未 (石川県立中央病院 腫瘍内科)
P26-2	Fluctuating PD-1 ratio in blood may predict clinical outcome of upper gastrointestinal cancer patients under ICI therapy Hiroaki Tanioka (Department of Clinical Oncology, Kawasaki Medical School) 谷岡 洋亮 (川崎医科大学 臨床腫瘍学教室)
P26-3	Paclitaxel plus Ramucirumab vs Paclitaxel plus Placebo Therapy in Metastatic Gastric Cancer: A Systematic Review Fenia Tandy (Faculty of Medicine, Pelita Harapan University)
P26-4	Efficacy of single agent chemotherapy TS-1 in patients with advanced and recurrent gastric cancer Anh Dinh (Department of Optimal Therapy, Cancer Research and Clinical Trials Center, VietNam National Cancer Hospital)
P26-5	A retrospective analysis of clinical features of unresectable gastric cancer with and without peritoneal carcinomatosis Shin Takahashi (Department of Medical Oncology, Tohoku University Hospital) 高橋 信 (東北大学病院 腫瘍内科)
P26-6	Docetaxel, cisplatin and capecitabine (DCX) for advanced gastric cancer followed by gastrectomy Yao Liang (Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital) 梁 瑤 (名古屋大学医学部附属病院 化学療法部)
P26-7	Fibrinogen to Albumin Ratio as a Prognostic Marker in Gastric Cancer Patients : A Systematic Review and Meta-Analysis Regan Elbert (Faculty of Medicine, Pelita Harapan University)
P26-8	Retrospective study of ramucirumab plus paclitaxel or ramucirumab plus nab-paclitaxel in gastric cancer Shonosuke Wakayama (Department of Medical Oncology, Tohoku University Hospital / Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University / Department of Clinical Oncology, Tohoku University School of Medicine) 若山 祥之介 (東北大学病院 腫瘍内科 / 東北大学加齢医学研究所 臨床腫瘍学分野 / 東北大学大学院医学系研究科 臨床腫瘍学分野)
P26-9	The Overall Survival of Paclitaxel plus Ramucirumab Therapy in RAINBOW subgroup of Gastric Cancer: A Systematic Review Celine Chrystelle (Faculty of Medicine, Pelita Harapan University)

Day 1 (Thu)

Day 2 (Fri)

Day 3 (Sat)

Room 1

Room 2

Room 3

Room 4

Room 5

Room 6

Room 7

Room 8

Room 9

Room 10

Room 11

Room 12

Room 13

Meet the Experts

Poster

P27

Gastrointestinal Cancer (Colorectal Cancer 1)
消化器(大腸1)

- P27-1 **RAS status in ctDNA during chemotherapy for RAS mutant colorectal cancer: A retrospective study**
Suguru Hirose (Department of Gastroenterology, Faculty of Medicine, University of Tsukuba)
化学療法既治療のRAS 変異型切除不能進行・再発大腸癌における血中RAS ステータスを評価する後方視的検討
廣瀬 優 (筑波大学 医学医療系 消化器内科)
- P27-2 **OncoBEAM RAS CRC kit use for detecting RAS mutation in patients with metastatic colorectal cancer: A retrospective study**
Kentarō Kawakami (Department of Medical Oncology, Keiyukai Sapporo Hospital)
実地診療におけるONCOBEAM RAS CRCキットの意義
川上 賢太郎 (恵佑会札幌病院 腫瘍内科)
- P27-3 **CX3CR1^{high}SLAMF7⁺ type I-Collagen⁺ Macrophages Promoting Colitis-Associated Carcinogenesis**
Kensuke Hachiya (Department of Hematology and Oncology, Mie University Graduate School of Medicine)
蜂矢 健介 (三重大学大学院医学系研究科 血液・腫瘍内科学)
- P27-4 **The pro-tumor effect of MMP14 on tumor microenvironment in colorectal cancer**
Yusuke Makutani (Department of Surgery, Kindai University Faculty of Medicine)
大腸癌の腫瘍免疫微小環境におけるMMP14発現の影響
幕谷 悠介 (近畿大学医学部 外科)
- P27-5 **Clinical significance of PIWI-interacting RNA piR-37524 in colorectal cancer**
Lui Ng (Department of Surgery, The University of Hong Kong)
- P27-6 **A new subtype of colorectal cancer based of RAS/RAF, micro-satellite status, and mesenchymal type for far-advanced CRC**
Shuya Yano (Department of Clinical Oncology, Kawasaki Medical School / Center for innovative medicine, Okayama University Hospital)
RAS/RAF/Microsatellite statusに間葉型を加えた新しいサブタイプによる大腸癌の Precision Medicine
矢野 修也 (川崎医科大学 臨床腫瘍学/岡山大学病院 新医療開発センター)
- P27-7 **The lncRNA ZFAS1 regulates lipogenesis by binding polyadenylate-binding protein 2 (PABP2) to stabilize SREBP1 mRNA in CRC**
Yanwen Liu (Department of Oncology, Zhongda Hospital, Medical School of Southeast University)
- P27-8 **Effect of metformin on proliferation and growth of colorectal adenocarcinoma cells line SW620**
Bustanur Rosidi (Mochtar Riady Institute for Nanotechnology (MRIN) - Pelita Harapan University)
- P27-9 **CapeOX plus radiotherapy is a useful preoperative therapy for locally advanced rectal cancer**
Sho Takeda (Department of Gastroenterological Surgery, Okayama University Hospital)
武田 正 (岡山大学病院 消化器外科)

P27-10 **Association between bevacizumab-induced proteinuria and history of ramucirumab in colorectal cancer patients**

Yosuke Kito (Department of Medical Oncology, Ishikawa Prefectural Central Hospital)

進行大腸癌患者におけるベバシズマブによる蛋白尿とラムシルマブの前治療との関連

木藤 陽介 (石川県立中央病院 腫瘍内科)

18:00-18:45 Poster Session 28 / ポスターセッション 28

P28 Lung Cancer/Thoracic Cancer (EGFR TKI)
呼吸器 (EGFR TKI)

P28-1 **Improving survival in EGFR mutation-positive non-small cell lung cancer: Tokushukai REAL world Data project (TREAD 01)**

Kiyooki Uryu (Department of Medical Oncology, Yao Tokushukai General Hospital)

瓜生 恭章 (八尾徳洲会総合病院 腫瘍内科)

P28-2 **Prognostic markers among patients with ALK-positive non-small cell lung cancer receiving first-line alectinib**

Takayuki Takeda (Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital)

ALK陽性肺癌に対するアレクチニブによる1次治療での効果予測因子を検討する多施設共同後方視的観察研究

竹田 隆之 (京都第二赤十字病院 呼吸器内科)

P28-3 **Safety and efficacy of dabrafenib plus trametinib for *BRAF*^{V600E} mutated non-small cell lung cancer**

Fumie Shigematsu (Department of Thoracic Oncology, Aichi Cancer Center Hospital)

重松 文恵 (愛知県がんセンター呼吸器内科部)

P28-4 **Progression patterns and clinical outcome after alectinib treatment for ALK-positive advanced non-small cell lung cancer**

Hajime Oi (Department of Thoracic Oncology, National Cancer Center Hospital East)

大井 肇 (国立がん研究センター東病院 呼吸器内科)

P28-5 **Monitoring of Plasma EGFR Mutations during Osimertinib Therapy for NSCLC Patients with Acquired T790M Mutation**

Kana Watanabe (Department of Respiratory Medicine, Miyagi Cancer Center)

渡邊 香奈 (宮城県立がんセンター呼吸器内科)

P28-6 **Real-world evidence of crizotinib for ROS1- tested patients with non-small cell lung cancer in Japan**

Masahiro Morise (Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan)

森瀬 昌宏 (名古屋大学大学院医学系研究科 呼吸器内科)

P28-7 **Short-term efficacy of osimertinib (Os) in untreated EGFR mutation-positive NSCLC: A single institution experience**

Kazuhiko Shibata (Division of Medical Oncology, Dept. of Medicine, Kouseiren Takaoka Hospital)

未治療EGFR遺伝子変異陽性非小細胞肺癌 (EGFRmNSCLC) に対するosimertinib (Os) の短期治療効果に関する検討

柴田 和彦 (厚生連高岡病院 腫瘍内科)

Day 1 (Thu)

Day 2 (Fri)

Day 3 (Sat)

Room 1

Room 2

Room 3

Room 4

Room 5

Room 6

Room 7

Room 8

Room 9

Room 10

Room 11

Room 12

Room 13

Meet the Experts

Poster

P28-8	Efficacy and safety of readministration of osimertinib after osimertinib resistance in non-small cell lung cancer Yu Tanaka (Department of Thoracic Oncology, National Cancer Center Hospital East) 田中 悠 (国立がん研究センター東病院 呼吸器内科)
P28-9	Efficacy and toxicity of EGFR-TKI in frail NSCLC with EGFR mutation: a retrospective analysis in a single institution Yuki Akazawa (Department of Thoracic Oncology, NHO Osaka Toneyama Medical Center) 赤澤 結貴 (大阪刀根山医療センター 呼吸器腫瘍内科)
P28-10	Survival Difference between EGFR Exon 19 Deletion and Exon 21 Mutation in Advanced Non-small Cell Lung Cancer Patients Dawn Lynn P. Guardiario (Section of Medical Oncology, St. Luke's Medical Center)
P28-11	The therapeutic efficacy of osimertinib in non-small cell lung cancer with malignant pleural effusion Hiroaki Nagamine (Department of Respiratory Medicine, Graduate School of Medicine, Osaka City University) 長嶺 宏明 (大阪市立大学大学院医学研究科 呼吸器内科学)
P28-12	Efficacy of dacomitinib on rechallenge as EGFR-TKI to NSCLC with EGFR mutation except of T790M mutation Taro Yoneda (Respiratory Medicine, Komatsu Municipal Hospital) 米田 太郎 (国民健康保険小松市民病院 呼吸器内科)
P28-13	Clinicopathologic Profile of Filipino Patients with EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer Kenneth G. Samala (Section of Medical Oncology, UP-Philippine General Hospital)
P28-14	Long-term response to alectinib in a patient with ALK-fusion gene emerged in afatinib-resistant EGFR mutated lung cancer Emiko Uji (Department of General Internal Medicine 4, Kawasaki Medical School) 宇治 恵美子 (川崎医科大学 総合内科学4)
18:00-18:45 Poster Session 29 / ポスターセッション 29	
P29	Lung Cancer/Thoracic Cancer (ICI efficacy 1) 呼吸器 (ICI 有効性1)
P29-1	LIGHT-NING: An observational study of nivolumab plus ipilimumab with or without chemotherapy for 1st line NSCLC in Japan Takashi Kijima (Department of Respiratory Medicine and Hematology, Hyogo College of Medicine) 木島 貴志 (兵庫医科大学病院 呼吸器内科)
P29-2	Significance of maintenance therapy following induction immunochemotherapy for advanced NSCLC patients Ryota Nakamura (Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine) 中邨 亮太 (京都府立医科大学大学院医学研究科 呼吸器内科学)
P29-3	Atezolizumab, bevacizumab, carboplatin, and paclitaxel for advanced NSCLC harboring EGFR mutations after TKI failure Yoh Yamaguchi (Department of Thoracic Oncology, National Cancer Center Hospital) 山口 曜 (国立がん研究センター中央病院 呼吸器内科)

- P29-4 **Real-world data of first-line treatment with pembrolizumab for NSCLC with high PD-L1 expression (HOT/NJLCG2001)**
Yasuo Kitamura (Department of Respiratory Medicine, Kushiro City General Hospital)
北村 康夫 (市立釧路総合病院 呼吸器内科)
- P29-5 **Efficacy of immune checkpoint inhibition in patients with advanced NSCLC with KRAS, MET, other minor driver alterations**
Yuji Uehara (Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital)
上原 悠治 (都立駒込病院 呼吸器内科)
- P29-6 **Efficacy of immunochemotherapy for patients with advanced NSCLC harboring oncogenic driver alterations**
Tae Hata (Department of Respiratory Medicine, Rakuwakai Otowa Hospital)
畑 妙 (洛和会音羽病院 呼吸器内科)
- P29-7 **Therapeutic effects and prognostic factors of immune checkpoint inhibitors for NSCLC with oncogenic driver fusions**
Hironori Satoh (Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan)
ドライバー融合遺伝子陽性非小細胞肺癌に対する免疫チェックポイント阻害薬の治療効果と効果予測因子についての検討
佐藤 大希 (国立がん研究センター中央病院 呼吸器内科)

18:00-18:45 Poster Session 30 / ポスターセッション 30

P30

Rare Cancer/Cancer of Unknown Primary (Case Report 2)
希少がん・原発不明がん(ケースレポート2)

- P30-1 **A case of anal duct cancer with administered only once Pembrolizumab that achieved CR on the CT image**
Kensuke Saito (Department of Medical Oncology, Hirosaki University)
Pembrolizumab単回投与で画像上CRを達成した再発肛門管癌の1例
斎藤 洵介 (弘前大学医学部附属病院腫瘍内科学講座)
- P30-2 **A case report of adrenocortical carcinoma treated based on the suggestion of cancer multi-gene panel testing**
Kento Toide (Department of Internal Medicine, Anjo Kosei Hospital)
副腎皮質がんに対してがん遺伝子パネル検査で示された治療が奏功した症例
戸出 健斗 (安城更生病院 内科)
- P30-3 **A case of lenvatinib-related heart failure in a patient with thyroid cancer**
Takeshi Kotake (Department of Medical Oncology, Kansai Electric Power Hospital)
レンバチニブによる心不全を発症した甲状腺癌の1例
古武 剛 (関西電力病院 腫瘍内科)
- P30-4 **Two cases of Desmoplastic small round cell tumor experienced at Shimane University Hospital**
Fumimasa Takahashi (Department of Medical Oncology, Shimane University)
当院で経験したDesmoplastic small round cell tumor の2例
高橋 史匡 (島根大学医学部附属病院 腫瘍内科)

Day 1 (Thu)	P30-5	An adult case of rhabdomyosarcoma on the face resected with chemoradiotherapy Yuta Ishiyama (Department of Medical Oncology, Kameda Medical Center) 若年成人に発症し、集学的治療によって切除に至った頬部横紋筋肉腫の一例 石山 雄太 (亀田総合病院腫瘍内科)
Day 2 (Fri)	P30-6	Diagnostic and therapeutic challenges of glioblastoma as an initial presentation of CMMRD Shumpei Onishi (Department of Neurosurgery, National Hospital Organization, Kure Medical Center and Chugoku Cancer Center / Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University) 膠芽腫を初発とするCMMRDの診断と治療の課題 大西 俊平 (呉医療センター中国がんセンター脳神経外科/広島大学 大学院医系科学研究科 脳神経外科)
Day 3 (Sat)	P30-7	SMARCA2/BRM-deficient undifferentiated/rhabdoid carcinoma of unknown primary site: a case report Yasutaka Tono (Department of Medical Oncology, Mie University Hospital) 原発不明のSMARCA2/BRM欠損未分化/ラブドイド腫瘍の一例 戸野 泰孝 (三重大学医学部附属病院 腫瘍内科)
Room 1	P30-8	Sarcomatoid changes of pulmonary squamous cell carcinoma to pulmonary spindle cell carcinoma Katsuharu Tono (Department of Hematology, Ikeda City Hospital) 東野 克温 (市立池田病院 血液内科)
Room 2	P30-9	A case of thymic adenocarcinoma that responded to lenvatinib therapy Yuhei Yamaguchi (Nagoya Medical Center) 胸腺腺癌に対してレンバチニブが著効した一例 山口 祐平 (名古屋医療センター)
Room 3	P30-10	Adrenocortical carcinoma mimics metastatic gastric adenocarcinoma Takayo Ota (Department of Medical Oncology, Izumi City General Hospital) 大田 隆代 (和泉市立総合医療センター 腫瘍内科)
Room 4	18:00-18:45 Poster Session 31 / ポスターセッション 31	
Room 5	P31 Gynecologic Cancer 1 婦人科1	
Room 6	P31-1	Psychosocial aspects in relation to ovarian cancer patients after covid pandemic in South India-Observational study Chandralekha Krishnan (Department of Medical Oncology, Madras Medical College)
Room 7	P31-2	Karyopherin Alpha 2 (KPNA2) Predicts Prognosis in Ovarian Cancer Patients: A Systematic Review and Meta-Analysis Michael G. Lokanata (Faculty Medicine, Pelita Harapan University)
Room 8	P31-3	Factors affecting adverse effects in PARP inhibitors medication Emiko Oka (Departments of Obstetrics and Gynecology, Osaka University) 岡 愛実子 (大阪大学 産婦人科)
Room 9	P31-4	Differentiated Omental-Derived Adipose Stem Cells-Conditioned Medium Promotes Ovarian Cancer Migration and Angiogenesis Su chin Tham (Institute of Molecular and Cell Biology, A*STAR, Singapore)
Room 10	Meet the Experts	
Room 11	Poster	

- P31-5 **Situation of Cervical Cancer in Mittaphab Hospital, Vientiane Capital city, Lao PDR in 2017-2020, a retrospective study**
Viengsavanh Vieng Khammounheuang (Department of Gynecologic-Oncology, Cancer Center, Mittaphab Hospital)
- P31-6 **Gynecological cancers diagnosed during treatment of other cancers**
Yoko Hasumi (Department of Obstetrics and Gynecology, Mitsui Memorial Hospital)
他臓器癌再発の鑑別にて診断された婦人科癌の2例
荷見 よう子 (三井記念病院)
- P31-7 **Pembrolizumab treatment in patients with gynecologic cancer: a single-institution experience**
Mariya Kobayashi (Department of Obstetrics and Gynecology Osaka University Graduate School of Medicine)
小林 まりや (大阪大学大学院医学系研究科産科学婦人科学教室)